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The development of prostate cancer (PCa) can be considered a co-evolution of both the 
epithelial and stromal cells; indeed, the latter develop their own unique gene signature during cancer 
progression that has potential predictive value in determining a patient’s outcome. Cancer-associated 
“reactive” stroma is characterized by heterogeneity in Transforming Growth Factor β (TGFβ) signaling, 
transdifferentiation into a myofibroblast phenotype by stromal fibroblasts, and an increased production 
of reactive oxygen species (ROS). In this study, we sought to examine the basis for PCa cell response to 
reactive prostate stromal cells (i.e. myofibroblasts) in vitro. Specifically, we have shown that human 
prostate derived fibroblastic (i.e. PS30) and myofibroblastic (i.e. WPMY-1) cell lines and primary stromal 
cells have the capacity to inhibit DU145 PCa cell motility in co-culture through the production of a 
precursor ligand for estrogen receptor β (ERβ). Activating the ERβ pathway in adjacent DU145 cells leads 
to induction of the cell adhesion molecule E-cadherin and a subsequent reduction in cell motility. 
However, an increased responsiveness to TGF-β1 in WPMY-1 cells triggers induction of COX-2 expression 
and elevated ROS production, which ultimately raises extracellular H2O2.  H2O2 derived from WPMY-1 
cells acts in a paracrine manner to decrease the recruitment of ERβ to the E-cadherin promoter in co-
cultured DU145 cells, as revealed by chromatin immunoprecipitation assays. shRNA knockdown of COX-
2 in WPMY-1 cells abolishes the TGF-β1-induced ROS production and restores the inhibitory effects of 
myofibroblasts on DU145 cell motility in co-culture. Therefore, despite their “reactive” stroma 
phenotype, limiting the TGFβ-driven ROS production in WPMY-1 cells restores their inherent capacity to 
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limit tumor progression through a local endocrine network targeting ERβ in adjacent PCa cells. Our 
results imply that controlling the redox status of the local milieu may offer a route for utilizing inherent 
regulatory mechanisms to limit cancer cell motility, ultimately acting to reduce its spread and 
dissemination. 
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1.0 Introduction 
Despite the broad range of current available therapies, prostate cancer (PCa) remains a major 
source of morbidity and mortality among men. It is second only to lung cancer in tumor-associated 
deaths among males [1]. Public health officials predict a dramatic increase in the incidence of prostate 
cancer in the coming years, underscoring the need for more effective therapies [2].  
In order to develop improved targeted therapies, a more thorough understanding of the 
molecular pathogenesis of prostate cancer is necessary. First-line therapy for most localized prostate 
cancer cases is radical prostatectomy, in which the entire prostate gland is surgically removed. However, 
recurrent disease or delayed diagnosis are generally widespread and are therefore targeted by systemic 
androgen-deprivation therapy. While initially effective, androgen-deprivation ultimately leads to 
androgen-independent disease, at which point therapy becomes palliative. The entire process of 
recurrence, initial androgen dependence, and ultimately androgen-independence speaks of an intricate 
molecular interplay of various factors that cause a continual evolution in the phenotype of the disease. 
Understanding these molecular pathways at any given point can provide a druggable target for specific 
therapy set to disrupt the continuum of disease. 
In this project, I sought to understand the molecular mechanisms underlying advanced, androgen-
independent disease. It is at this point, after the failure of all current therapies, that the disease is the 
least well understood and the current therapeutic modalities are the least effective.  
1.1 The Prostate Gland: Structure and Function 
1.1.1 Normal Growth and Development 
The male reproductive tract is formed from the urogenital sinus (UGS) in response to fetal 
androgens [3].  The production of testosterone stimulates the budding of prostate epithelium from the 
UGS, which expresses high levels of androgen receptor (AR) during that development period [4]. By the 
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11th week of development, in response to high levels of circulating testosterone, the mesenchymal cells 
begin to differentiate into the smooth muscle and fibroblasts that form the stroma [5, 6]. The adult 
prostate maintains AR expression, and signaling through the AR regulates new growth to replace the 
constant turnover of cells in the organ. In early adulthood, the testes are significant contributors of 
testosterone and subsequent AR activation in the prostate. In older men, adrenal synthesis of DHEA and 
its subsequent conversion to the potent androgen metabolite dihydrotestosterone (DHT) is the major 
source of AR ligand [7, 8].   
In the normal adult prostate, there is a glandular epithelial component and a fibromuscular 
stroma. The epithelial cells lining the glands express AR and are the source of prostate specific antigen 
(PSA), which is currently a biomarker for prostate health. They are arranged into a neatly delineated 
squamous basal layer and columnar secretory layer. The stromal compartment comprises both 
fibroblasts and smooth muscle cells, with a predominance of the latter, arranged into an organized 
orientation of fibers [9]. In 1981, McNeal proposed the concept of a zonal anatomy of the adult 
prostate, partitioning it into 4 zones based on their location and embryonic structure of origin: the 
peripheral , central, transition, and peri-urethral zones [10]. The former 2 zones comprise the glandular 
part of the prostate and account for ~95% of its total size. This zoning anatomy is currently still used to 
describe where prostate cancers are located, with the greatest percentage of neoplasias occurring in the 
large peripheral zone [4]. 
Figure 1 shows H&E stained microscopic slides of normal and cancerous prostate anatomy 
(http://library.med.utah.edu/WebPath/TUTORIAL/PROSTATE/PROSTATE.html#4). The normal specimen 
demonstrates a clearly defined epithelial-lined gland surrounded by an organized fibromuscular stroma, 
whereas the PCa specimen shows a loss of normal glandular architecture, a loss of structure in the basal 
and secretory epithelia, and infiltrating immune cells (stained red). 
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Figure 1. Tissue staining of normal and cancerous specimens from excised human prostate samples. 
A. H&E stained microscopic slide of normal prostate gland demonstrating normal gland 
architecture in the left portion of the specimen. A squamous basal epithelial layer separates the 
secretory columnar epithelium from a fibromuscular stroma. 
B. H&E stained microscopic slide of a poorly differentiated prostate carcinoma. Note the loss of 
normal glands separated by areas of organized stroma. The glands appear smaller and have lost 
the basal epithelial layer. Red staining indicates infiltration by immune cells (arrowheads). 
 
1.1.2 PIN and Carcinogenesis 
Most prostate cancers are glandular/epithelial in nature and are therefore classified as 
adenocarcinomas. Histologically, a precursor to PCa is prostatic intraepithelial neoplasia (PIN), 
characterized by a thickening of the epithelial layer and a loss of distinct basal and secretory layering. 
Since PIN retains the basal membrane separating the epithelium from the stroma, it is not considered 
cancerous. However, high-grade PIN is considered a cancerous precursor [4]. 
Most prostate cancers are multi-focal, meaning they have multiple locations within the gland and are 
often separated by areas of normal prostate anatomy. In order to determine the extent to which the 
prostate is affected in a particular patient, 12-site needle biopsies are obtained and scored. A 
pathologist reviews each biopsy sample, and a number of cancer-containing out of total samples 
A
. 
B
. 
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obtained is expressed: e.g. 7/12. Within the cancerous specimens, a modified Gleason grading system is 
employed. A pathologist grades the extent of architectural disarray 1-4, with 4 being complete loss of 
structure, and will assign a number representing the most commonly observed number and another 
representing the most severe loss of differentiation. The grades are then added together to give a final 
score: e.g. Gleason score 2 + 4 = 6 [11]. 
While many prostate cancers are developed late in life, are slow growing, and remain organ-
confined for the extent of the patient’s life, others are aggressive and may spread rapidly. Partin tables 
have been developed to predict the probability of a patient having organ-confined disease based upon 3 
parameters at diagnosis: clinical stage, biopsy Gleason score, and serum PSA level [12, 13]. These 
models are clinically useful in determining a patient’s risk of developing aggressive or advanced disease, 
and may help guide the clinician in his/her treatment paradigm. A fast-growing or aggressive tumor will 
initially break free of the prostate tissue capsule, at which point it begins with a local spread to nearby 
lymph nodes and urinary tract structures. Eventually PCa will metastasize to distal organs, most often 
forming osteoblastic lesions in the skeleton, though many cases of dural PCa metastases have been 
reported [14, 15]. A patient’s risk of relapsing into this late-stage disease is inversely related to the 
presence of extraprostatic extension, seminal vesicle extension, positive lymph nodes, or positive 
margins at surgery [16]. 
While PCa is diagnosed on biopsy by a loss of tissue architecture and the presence of abnormal cells, 
on a molecular level it is marked by genetic alterations and a decrease in apoptosis,  which ultimately 
lead to this observed cellular dysplasia and tissue disorganization [4].  Deregulation of androgen 
signaling is a molecular hallmark of advanced disease, and will be discussed in further detail in the 
subsequent section. 
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1.2 The role of androgens in prostatic carcinoma 
1.2.1 Nuclear receptor structure and function 
Nuclear receptors are a superfamily of receptors that modulate transcription of various genes. 
The focus herein will be on a subgroup of nuclear receptors, the steroid hormone receptors (SRs). When 
bound to their respective ligand, the steroid hormone receptors translocate from the cytoplasm to the 
nucleus and initiate alterations in transcription of specific target genes. They contain a ligand-binding 
domain (LBD) and a DNA-binding domain (DBD), allowing them to display ligand-dependent activation 
and controlled regulation of specific target genes [17]. Emerging insight into nuclear translocation has 
revealed that SRs possess both nuclear localization and nuclear export sequences and are capable of 
nucleocytoplasmic shuttling. It is thought that nuclear export is one way in which gene transcription is 
terminated [18].  SRs have distinct functions in both the cytoplasm and the nucleus, with the latter being 
activity as a transcription factor involving direct DNA binding and transcriptional complex recruitment at 
specific target genes [19]. In the cytoplasm, SRs are bound by heat-shock proteins (HSP) and are in 
monomeric form. Upon ligand binding, the HSP are shed and the receptors translocate to the nucleus 
[20] . When part of an active transcriptional complex, SRs exist in homo- or heterodimers. While this 
dimerization can occur in either the cytoplasm or the nucleus, it is a necessary component for 
transcriptional activity. Tissue-specificity of nuclear receptor action is regulated by expression of various 
coactivators and corepressors, and different target genes can be differentially activated or repressed 
depending upon the specific composition of the transcriptional complex [21]. Figure 2 shows a diagram 
of nuclear receptor activation and target gene regulation.  
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Figure 2. A simplified schematic of nuclear receptor signaling. Upon entering the cell, hormone is able 
to bind its specific nuclear receptor. This induces shedding of heat shock proteins (HSP) and allows the 
receptors to homo- or heterodimerize. The dimerized receptors then recognize a specific hormone 
response element (HRE) in the promoter region of a target gene. Recruitment of appropriate 
transcriptional machinery, including coactivators, polymerases, etc., will then initiate gene transcription. 
 
Currently there are 48 members of the human nuclear receptor superfamily [22], but our focus 
here will be on the subset of endocrine nuclear receptors, primarily the androgen receptor (AR) and 
estrogen receptor subtype beta (ERβ). Due to the highly conserved structure of nuclear hormone 
receptors, endogenous hormone ligands are often capable of binding multiple receptor subtypes; 
however, ligands often display differential binding affinities for the various receptors, and thus at 
physiologic concentrations specificity is achieved due to preferential binding of the ligand to the 
receptor for which it has the lowest Kd [23].  
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Additionally, steroidogenesis is an intricate and tightly controlled process. Differential enzyme 
expression in various tissues allows metabolism that either activates or inactivates various steroid 
hormone precursors into ligands that will preferentially bind the nuclear hormone receptor of 
importance in that tissue. In the prostate, for example, the enzyme 5α-reductase is highly expressed. 
5α-reductase converts testosterone into dihydrotestosterone (DHT), a ligand much more potent for the 
AR than testosterone [24, 25]. Unlike testosterone, DHT is unable to be converted to estradiol by the 
enzyme aromatase [26], thus expression of 5α-reductase ensures adequate activation of AR in the 
prostate while preventing the production of ligands for the estrogen receptor (ER).  
The androgen receptor is highly expressed in androgen-responsive tissues, such as those found 
in the male reproductive organs. During development and again during puberty, circulating levels of 
androgens are extremely high as the primary and secondary sex organs develop and mature [27, 28]. In 
the adult male prostate, androgens regulate the normal cycle of cell growth, maturation, and death [8].  
As evidence of AR activity being intimately involved in prostate growth, a target gene of AR, prostate 
specific antigen (PSA), is currently used as a screening marker for hyperproliferative diseases of the 
prostate (PIN, PCa, and benign prostatic hyperplasia, BPH) [29]. The following section will address the 
complicated biphasic role of AR in prostate cancer in more detail. 
1.2.2 Androgen dependence and deregulation 
As previously mentioned, in the adult prostate AR signaling is vital to the maintenance of normal 
growth and function. Prostate epithelial cells are undergoing a constant low level of turnover, and 
androgen signaling is crucial for the stimulation of new cell growth and development. Due to this growth 
and developmental function of AR, it is to be expected that in prostate cancer an abundance of AR 
signaling underlies the overgrowth of epithelial cells seen in carcinogenesis. Initially, the abundance of 
AR activity is detected by increased serum levels of PSA, an AR target gene.  During this early stage of 
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disease, multiple factors can contribute to the hyperactivity of AR. Mutations within the AR gene can 
lead to a more promiscuous receptor which can be activated in the absence of ligand, or by additional 
growth factors such as EGF and IGF-1 [30-34]. Increased expression of AR-specific co-activators and/or 
alterations in post-translational modifications can also be the source of aberrant AR signaling in early 
prostate cancer [35].  
While initial therapy for PCa is removal of the organ, recurrent disease is a common problem. 
Without a localized target tissue, the recurrent cancer cells, which are still dependent upon androgen 
signaling for continued growth, are typically targeted through systemic androgen deprivation [36].  This 
chemical castration is achieved by administration of either a GnRH agonist, a 5α-reductase inhibitor, or a 
specific AR-antagonist [37, 38]. The former two lead to an overall decrease in endogenous production of 
androgens, whereas the latter targets the ability of circulating androgens to effectively activate the AR.  
This chemical castration is initially effective, but after prolonged androgen deprivation eventually the 
metastatic disease becomes castration resistant and unresponsive to this therapeutic approach [39]. 
Castration-resistant disease, however, is still dependent upon androgen receptor signaling; it is the 
therapeutic approach to ablating androgen activation that loses efficacy, as aberrant AR activation 
resumes despite the modalities employed for chemical castration [40]. Patients with CRPC still exhibit 
activation of AR target genes (e.g. PSA), thus demonstrating that AR is still active in the course of the 
disease despite a therapeutic attempt to remove potent circulating androgens.  
Recent research has further complicated the role of AR in PCa through an intricate series of 
highly specific AR-knockouts in mice. While its results still remain a hot area of debate, a detailed study 
by Niu et al. has shown that AR in the prostatic epithelium is tumor suppressive, whereas AR in the 
prostatic stroma promotes invasion by a cancerous epithelium [41]. Interestingly, additional follow-up of 
these results led to the hypothesis that one of the mechanisms through which AR alters epithelial 
20 
 
invasive characteristics is through modulation of TGFβ signaling. A subset of TGFβ responsive genes, 
including COX-2 (which will be addressed in more detail in a subsequent section), are not upregulated 
following TGFβ treatment when AR is stably re-expressed in PC3 PCa cells [41]. These TGFβ responsive 
genes act to promote tumor aggressiveness, thus inhibiting their induction via re-expression of AR acts 
in a tumor-suppressive manner. Androgen signaling, even in castration-resistant disease, appears to be a 
two-edged sword. Clearly, studies such as these would argue against global androgen deprivation 
therapy, again underscoring the need for a more thorough understanding of prostate cancer growth and 
progression to develop more targeted and efficacious therapies.  
1.2.3 Estrogen receptor in the prostate 
Estrogen receptor (ER) is similar to AR in conserved nuclear receptor structure and function, but 
its natural ligands are estrogenic in nature, such as estradiol. Estrogens can be synthesized from adrenal 
androgens in peripheral tissues through the action of the enzyme aromatase. As men age, their 
circulating levels of testosterone naturally decline, but the stable expression of aromatase ensures that 
estrogen levels remain constant [42]. Thus, in the ageing male population, the role of estrogen as a 
regulatory steroid within hormone-dependent tissues such as the prostate becomes increasingly 
important. Additionally, laser capture microdissection of normal human prostate tissue has identified 
aromatase expression in normal stromal cells; in PCa, malignantly transformed cells also acquire 
aromatase expression [43]. This expression pattern ensures local synthesis of estrogens within the 
prostate, highlighting their importance in prostate biology. 
ER exists in 2 subtypes designated as ERα and ERβ. Unlike AR, whose activation is associated 
with prostate growth, signaling through ER appears to be more complex, lending in large part to 
differential activities of the ER subtypes. ERα activation in the prostate is associated with three distinct 
responses: aberrant proliferation, inflammation, and cancer [42].  Knockout of aromatase in a mouse 
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model (ArKO) leads to lifelong increased levels of androgens, yet the mice fail to develop prostate 
cancer [44]. Administration of synthetic estrogens early in development, however, leads to abnormal 
prostate biology later in life in these same ArKO mice [45].  These studies suggest that it is not a singular 
steroid hormone pathway that is responsible for growth and maintenance of the prostate, but rather 
that it may be the balance between androgenic and estrogenic signaling that underlies steroid signaling 
in prostate biology. 
In the prostate, the prevailing ER subtype is ERβ [46, 47]. Knockout mice have been generated 
that are deficient only in the ERβ subtype, and extensive studies performed with these models have 
shown that while ERα mediates estrogen-induced prostatic inflammation and pathologies, ERβ may 
confer a beneficial effect in maintenance of normal homeostasis [42]. Supporting epidemiological 
evidence also exists, as men who consume higher dietary intakes of phytoestrogens (weakly estrogenic 
compounds that exhibit a significantly higher affinity for ERβ over ERα) exhibit a lower incidence of PCa 
[48, 49]. 
A unique feature of ERβ is its sensitivity to oxidation. This reportedly high redox sensitivity of 
ERβ may be important in tumors or tissues  exposed to chronic inflammation (to be discussed in detail in 
a later section). In particular, chronic inflammation leads to increased levels of reactive oxygen species 
(ROS) and subsequent development of an oxidizing milieu. Keeping this in mind, the oxidation-sensitive 
motifs in ERβ may be of particular relevance in PCa.  Kumar et al. showed that oxidative stress in PCa 
cells is required for an aggressive phenotype, and that PCa cells are capable of generating high levels of 
ROS [50]. Thus, ERβ in the prostate could potentially be susceptible to oxidation through inherent 
generation of ROS. 
Zinc-finger motifs are a common feature among the nuclear receptor family of transcription 
factors [51]. In ERβ, the first zinc-finger is necessary for DNA binding and the second zinc-finger is 
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responsible for receptor dimerization, an essential step for stabilization of DNA binding at the promoter 
[51, 52]. With a high number of cysteine residues, these motifs are particularly susceptible to oxidation. 
Oxidation at a cysteine residue results in the loss of 2 protons and subsequent formation of a disulfide 
bond, and this structural change induces alterations in the protein structure. Specifically, ERβ oxidation 
occurs primarily in the 2nd zinc finger motif, and the resulting conformational change in protein structure 
de-stabilizes and ultimately prevents DNA binding [52, 53]. Electromobility shift assays (EMSA) have 
demonstrated a loss of DNA-binding when ERβ is subjected to oxidation by H2O2 [52]. This redox-
sensitivity has been extensively studied in breast cancer, and it has been shown that up to one-third of 
untreated ER-positive breast cancer tumors have structurally altered ER that is unable to bind its 
cognate DNA sequence at its target genes [54]. This effect is reversible with addition of reducing agents, 
and in vitro studies have isolated breast cancer tumors with non-functional ER and restored DNA binding 
activity through vigorous treatment with the thiol reducing agent, DTT [55].  
Activation of ERβ by estradiol is suppresses prostate epithelial cell growth, and activation of the 
receptor by androgen metabolites inhibits cell motility by increasing cell adhesion [56, 57]. Specifically, 
ERβ activation by androgen metabolites increases expression of E-cadherin, an epithelial marker 
associated with cell adhesion [58]. Loss of cell adhesion and increased motility are hallmarks of 
carcinomas, thus ERβ could potentially serve to limit carcinogenesis in the prostate by maintaining 
adequate expression of E-cadherin and hence inhibiting the generation of a more motile phenotype.  
Moreover, recent work has shown that androgen metabolites can be potent activators of the 
ERβ subtype, and in the prostate these androgen derivatives act as the endogenous ERβ ligands [46, 59]. 
Specifically, 2 DHT metabolites, 5α-androstane-3α,17β-adiol (3α-Adiol) and 5α-androstane-3β,17β-adiol 
(3β-Adiol), have been shown to be potent ERβ ligands [58, 59]. Activation of ERβ in the prostate is 
ensured by local tissue expression of the enzymes AKR1C2 and AKR1C3, which are responsible for the 
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metabolism of DHT into 3α-Adiol and 3β-Adiol, respectively [60, 61].  The importance of these 
metabolites as ERβ ligands is underscored by the fact that the local concentration of 3β-Adiol in the 
prostate is one hundred fold higher than that of estradiol [56]. Interestingly, these steroid-converting 
enzymes are of growing interest in prostate cancer. Polymorphisms in these enzymes have been 
correlated with prostate cancer risk [62], and recent endeavors to identify small molecule modulators 
have been undertaken using modern high-throughput screening techniques [63].  
More recent work has demonstrated another ERβ-dependent signaling pathway active in 
prostate cancer which may serve to limit tumor aggressiveness. Epithelial-to-mesenchymal transition 
(EMT) is a crucial early step in the acquisition of a more motile and invasive phenotype, hence 
permitting cancer cells to migrate and invade surrounding tissues. ERβ activation downregulates TGFβ 
and hypoxia induced EMT through regulation of Vascular Endothelial Growth Factor (VEGF) promoter 
[56]. An inverse relationship exists between ERβ expression and the progression of prostate cancer to a 
high Gleason grade [56]; thus, signaling through ERβ appears to be one mechanism through which 
prostate growth is tightly regulated. Hence, this pathway presents a putative target for therapeutic 
intervention. Figure 3 shows the major steroidogenic and steroid metabolizing pathways active in the 
prostate. 
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1.3 The tumor microenvironment 
1.3.1 Tumor-stroma co-evolution 
The importance of the microenvironment in the fate and development of carcinomas is well 
recognized. Elegantly designed co-culture experiments by Gerry Cunha and collaborators demonstrated 
that, in the prostate, signaling from the microenvironment could “instruct” an initiated epithelial 
phenotype to become cancerous. Initiated epithelial cells (immortalized but non-tumorigenic) failed to 
form tumors in mice either alone or when co-transplanted with normal prostatic fibroblasts, but when 
co-transplanted with cancer-associated fibroblasts (CAFs) the mice underwent significant tumor 
development [64]. A later study designed by Petersen and Bissell showed that a normal stromal 
microenvironment could revert breast cancer cells back to a near normal phenotype when grown 
together in 3D co-culture [65]. It is well established that while it is the epithelial cells of the prostate that 
actually develop into cancer, the surrounding stromal fibroblasts co-evolve alongside this 
transformation and eventually differentiate into an altered form known as “myofibroblasts,” otherwise 
referred to as CAFs.  In addition to CAFs, the tumor microenvironment recruits inflammatory and 
immune cells, displays an altered production of and response to various growth factors and signaling 
molecules, and collectively develops into a “reactive” stroma [66].  
Under normal conditions in a healthy prostate, the stroma acts as a balance to keep the 
epithelium in check, secreting factors that limit cell proliferation, migration, etc. [65, 67]. However, upon 
malignant transformation, the transdifferentiated CAFs lose their ability to restrain the epithelium and 
Figure 3. A schematic of steroid metabolism in the prostate. The enzymatic profile of the prostate tissue 
allows de novo steroid synthesis as well as conversion among various steroids and steroid precursors. The 
main steroids and metabolites active in the prostate are represented in green. 
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instead acquire a permissive and/or supportive role in cancer progression. This reactive stroma evolves 
its own unique signature, including increased fibroblast growth factor (FGF2), connective tissue growth 
factor (cTGF), vimentin, smooth-muscle α-actin, and tenascin levels [68]. Current work is investigating 
the usefulness of the stromal signature in predicting both the initial development of prostate cancer as 
well as biochemical-free recurrence for patients following localized therapy [9, 68]. While the usefulness 
of the stromal signature as a clinical diagnostic tool is indeed interesting, it is perhaps more promising to 
attempt to understand the initial drivers of this stromal transdifferentiation.  Targeting the tumor 
microenvironment could provide a unique and specific alternative therapy and could potentially utilize 
the body’s own defenses to control the cancer proliferation and spread.  
Co-evolution of the stroma surrounding the tumor in the prostate is intimately related to three 
key factors: hypoxia, oxidative stress, and autophagy/mitophagy [69]. The focus here will be primarily 
oxidative stress. In vitro co-culture experiments involving human breast cancer cells and stromal 
fibroblasts demonstrated that cancer cells induce oxidative stress in adjacent fibroblasts, as measured 
by an increased production of reactive oxygen species (ROS) and DNA damage [70, 71].  In response to 
this increased production of ROS, neighboring cancer cells exhibit antioxidant defense responses, 
including increased production of the antioxidant enzyme peroxiredoxin1 and the anti-apoptotic protein 
TIGAR [69]. However, while the cancer cells demonstrate pro-survival responses, increased local ROS 
production by the stroma appear to prevail in oxidative stress, which is a function of the balance 
between ROS production and its catabolism by antioxidant enzymes and nutrients.  A complex area of 
research, per se, the intricacies of oxidative stress will not be explained in detail here. Suffice it to say 
that substantially elevated ROS levels result in cellular glutathione depletion whose effects are widely 
deleterious.  Germane to this discussion, it is reported that oxidative stress instigates additional DNA 
damage, thus contributing to increased genomic instability in both the cancer cells and the surrounding 
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stroma [72, 73]. Figure 4 below is a simplified diagram of the oxidative stress model of tumor-stroma co-
evolution. 
 
Figure 4. Oxidative stress model of tumor-stroma co-evolution. Cancer cells induce oxidative stress in 
adjacent stromal cells. This increases ROS production by the stroma, and the ROS species act as 
paracrine mediators to induce antioxidant defenses, random mutagenesis, and ultimately decreased 
apoptosis in neighboring cancer cells. It is postulated that elevated ROS production outweighs cancer 
cell antioxidant defenses leading to overall oxidative stress. This eventually leads to a shift in net energy 
usage, wherein the stroma becomes catabolic and the released nutrients are recycled to “feed” the 
anabolic cancer cells. 
 
Corroboration of this oxidative stress-driven model of tumor-stroma co-evolution lies in 
experiments demonstrating that oxidative stress response genes, such as Hypoxia Inducible Factor 1 
alpha (HIF1α) and Nuclear Factor kappa B (NFB), are activated in CAFs [71]. Additionally, activating 
both HIF1α and NFB in stromal fibroblasts was sufficient to confer a reactive, myofibroblastic 
phenotype, further underscoring the important role that oxidative stress plays in transforming a normal 
prostatic stroma into a cancer-supportive microenvironment [69]. 
1.3.2 Transforming Growth Factor β 
One key signaling mediator in the transdifferentiation of a stromal cell into a reactive cancer 
associated fibroblast (CAF) is the cytokine Transforming Growth Factor β (TGFβ) [66, 74].  TGFβ is a 25 
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kDa homodimeric secreted protein that binds to a set of heterodimeric receptors, initiating a signaling 
cascade that ultimately results in alterations in transcription of TGFβ responsive genes [75].  Figure 5 
shows a simplified schematic of canonical, Smad-dependent TGFβ signaling. An alternative Smad-
independent pathway also exists, generally understood to signal through ERK and p38 MAPK activation 
[76]. TGFβ is an active player in wound healing, tissue repair, and, as will be discussed in detail, cancer 
initiation and progression [65, 77, 78]. TGFβ has been shown to induce the phenotypic and morphologic 
change in the stromal microenvironment of the prostate known as transdifferentiation [66]. The 
resulting change in fibroblasts to a myofibroblast phenotype is defined by a co-expression of both 
fibroblastic and smooth muscle markers such as smooth muscle α-actin expression, tenascin, and 
vimentin [66, 79, 80], and it carries with it alterations in the stromal cells’ interactions with the 
cancerous epithelial cells [67]. In addition to mediating transdifferentiation of fibroblasts, TGFβ also 
induces the expression of several key pro-cancerous genes involved in cell adhesion, angiogenesis, and 
redox signaling [81]. 
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Figure 5. A simplified schematic of Smad-dependent TGFβ signaling. TGFβ binds to TGFβRII, which then 
heterodimerizes with TGFβRI. Following receptor cross-phosphorylation, receptor-associated Smads 
(Smad 2 and Smad 3) are phosphorylated, complex with the common Smad 4, and translocate to the 
nucleus. The Smad complex recognizes Smad binding elements in the promoter regions of target genes 
and, upon DNA binding, recruits transcriptional machinery to initiate gene transcription. 
 
TGFβ is unique among growth factors involved in prostate cancer because it appears to have a 
biphasic effect. In normal prostate and early carcinogenesis, TGFβ exerts a growth inhibitory effect. 
Treatment of prostatic epithelium with TGFβ prevents the cells from transitioning from G1 to S phase, 
and it is thought that in the normal prostate TGFβ is, in part, responsible for maintaining normal 
prostate size [75].  In some human cancers, loss of functional TGFβ signaling contributes to 
carcinogenesis. This has been demonstrated through loss of function mutations in TGFβ receptors, 
downregulation of Smad proteins responsible for propagating TGFβ signaling, overexpression of 
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negative regulators of the TGFβ pathway, and alterations in expression levels of co-activators and co-
repressors [77, 82-85]. These observations would lead  to the conclusion that TGFβ is capable of 
suppressing tumorigenicity, and a primary therapeutic goal would be to restore adequate TGFβ 
signaling. 
Paradoxically, however, tissue staining from both human and orthotopic rat models of PCa has 
shown a significantly higher level of TGFβ in cancerous versus normal tissue [75, 86], and cell lines 
derived from human prostate cancer, such as PC3 and DU145 lines, are known to produce relatively 
large amounts of the TGF-β1 isoform [87]. This has been demonstrated by both quantitation of mRNA 
transcript levels of TGF-β1 as well as direct measurement of secreted TGF-β1 by enzyme-linked 
immunosorbant assay (ELISA) [87].  Additionally, overexpression of TGFβ in prostate cancer correlates 
with increased risk of metastasis and worse prognosis [86], and staining for the phosphorylated form of 
Smad2 (indicative of active canonical TGFβ pathway activation) is highest in CAFs immediately 
surrounding cancerous foci in samples taken from prostate biopsy specimens [82]. While normal 
prostatic epithelium is growth suppressed by TGFβ, cancerous cells are immune to its growth inhibiting 
effects, thus allowing them to overproduce the cytokine yet evade any autocrine effects it may have on 
their growth [75].  As such, much attention has been directed to the effects of locally produced TGFβ on 
the prostatic stroma. As previously mentioned, TGFβ is sufficient to induce transdifferentiation of 
prostatic fibroblasts into reactive myofibroblasts. New research has outlined the concept of “stromal 
heterogeneity” in TGFβ signaling. Some stromal cells lose the ability to respond to local TGFβ, usually 
through loss of the TGFβ type II receptor (TGFβRII), while others maintain an intact TGFβ response 
pathway. With the loss of TGFβ response in some cells, the local production of TGFβ increases, thus 
having a more profound effect on those cells in which TGFβ signaling remains intact [82, 88]. This 
innovative concept succinctly explains the paradoxical observation that while advanced PCa is 
associated with a loss of TGFβ signaling pathway components, the local production of TGFβ is 
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significantly increased and there are focal points of increased TGFβ signaling, as evidenced by elevated 
phospho-Smad2 staining in CAFs surrounding tumor foci [82]. 
Taken together, these data suggest a complex role for TGFβ in the initiation and progression of PCa. 
Rather than target TGFβ signaling directly, which has been undertaken with disappointing clinical results 
thus far [89], downstream targets of the pathway should be carefully elucidated and more directly 
targeted. 
1.4 Inflammation 
1.4.1 Cancer as a wound that never heals 
When a tissue is injured, the immediate response by the body is activation of inflammatory 
pathways. This inflammation serves multiple key functions:  recruitment of immune cells to fight off 
potential infectious agents, removal of damaged cells and debris, stimulation of migration of cells into 
the wounded area, re-vascularization within the wound, and promotion of proliferation of the newly 
migrated cells to restore tissue integrity. Coordination of all of these processes is a tightly regulated 
mechanism, and in normal wound healing these pro-inflammatory signals are offset by anti-
inflammatory signals following successful repair of the wound. If the inflammation is not terminated, but 
instead enters a chronic state of unbalanced pro-inflammatory signaling, detrimental sequelae may 
result. Many human diseases, ranging from rheumatoid arthritis to obesity, are linked to chronically high 
levels of pro-inflammatory mediators. A current cancer model suggests that cancerous tissue may also 
posses this imbalance of pro- and anti-inflammatory signals, and in many respects cancer behaves 
simply as a wound that never heals [90]. 
The first step in wound repair is recruitment and activation of immune cells. This is 
accomplished through release of chemokines, which are cytokine growth factors that have a specific 
chemoattractant property for circulating immune cells. Once activated, the immune cells migrate out of 
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circulation and enter the wounded tissue. Binding of antigen to various toll-like receptors (TLRs) 
expressed on the immune cells activates a signaling cascade that leads to the production of 
inflammatory cytokines, such as tumor necrosis factor alpha (TNFα) and interleukins 1β and 6 (IL-1β and 
IL-6, respectively) [91, 92]. Following the propagation of pro-inflammatory signals, the immune cells 
then begin the processes of fighting off infection and removing dead or wounded cells and cellular 
debris. Immune cells can sterilize the wounded area through production of reactive oxygen and nitrogen 
species (ROS and RNS, respectively) and various proteases such as plasminogen and matrix 
metalloproteinases (MMPs) [93, 94]. These reactive species induce fatal DNA damage to engulfed 
bacteria, and the proteases serve to degrade the extracellular matrix to facilitate cell migration for a 
later step of wound repair. However, in cancerous tissue there is a distinct lack of bacterial presence, yet 
the production of ROS, RNS, and proteases continues to occur as if the tumor were in a chronically 
inflamed state [78]. Rather than supporting a healing process, these mediators can be damaging and 
actually prolong the state of inflammation with a feed-forward mechanism. As the tumor milieu 
becomes more reactive as a result of increased immune cell secreted factors, it initiates a state of injury 
and the body responds by further increasing production of inflammatory mediators. The ROS and RNS 
produced in the milieu can further propagate the cancer by initiating additional DNA mutations in the 
nearby cancer cells, and some studies have suggested that cancer cells posses a more sensitive stress 
response to ROS than their non-transformed counterparts [95]. 
In addition to extravasation of immune cells in response to chemotactic signals released by the 
wounded tissue, uninjured cells must also become motile and migrate into the wounded area to aid in 
restoration of tissue integrity. In normal wound healing, epithelial cells surrounding a wound acquire a 
more mesenchymal phenotype through an incomplete version of the process of epithelial to 
mesenchymal transition (EMT). This more mesenchymal phenotype is characterized by a loss of cell-cell 
adhesion, which directly increases their motility and allows them to migrate into the wound to restore 
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the epithelial layer [78, 90, 96]. During EMT, epithelial cells will lose expression of the epithelial marker 
E-cadherin and will begin to express markers of a mesenchymal lineage, such as N-cadherin, 
thrombospondin, vimentin, etc.  In addition, upregulation of β1 integrins permits the binding of the cells 
to the ECM to allow migration into the wound [96].  
In normal wound healing, however, this loss of E-cadherin and subsequent increase in motility is 
a transient process, and following re-epithelialization of the wound the migrated cells revert back to a 
normal epithelial phenotype [97]. Cancerous cells also undergo EMT and gain the mesenchymal 
properties associated with the transition such as loss of cell-cell adhesion, increased migratory capacity, 
increased invasion, etc [98]. Unlike normal wound healing, however, carcinoma cells do not receive the 
signal to revert back to a normal epithelial phenotype. They fail to re-express E-cadherin, and their 
ability to metastasize is promoted by enhanced migration and invasion into nearby blood and lymphatic 
vessels for hematogenous and lymphatic spread. The importance of E-cadherin expression in metastatic 
capacity was demonstrated by Onder et al., who showed that HMLER, a tumorigenic but non-metastatic 
breast cancer cell line, can become invasive and highly metastatic following specific shRNA knockdown 
of E-cadherin [99]. 
As the migrating cells enter the wound and begin to proliferate to restore tissue integrity, they 
need a steady supply of oxygen and nutrients to fuel the process. Angiogenesis is the process of 
sprouting new blood vessels from already existing ones, and it is crucial to the wound healing process. 
Arguably the most important player in the angiogenic process is Vascular Endothelial Growth Factor 
(VEGF), and its expression can be activated through multiple pathways, including TGFβ signaling as well 
as in response to hypoxia through regulation by HIF1α [56]. A common feature between cancer and 
wound healing is increased expression of VEGF; just as newly forming granulation tissue needs a blood 
supply, growing tumor tissue is also limited by the extent of its available blood supply [100]. In vivo 
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studies demonstrated the importance of VEGF in wound repair through specific deletion of the VEGF 
gene in a mouse model of skin carcinogenesis. Following deletion of VEGF, deficient wound repair was 
observed; interestingly, the mice also demonstrated a resistance to the development of chemically 
induced skin cancer [101]. In contrast, overexpression of VEGF in mice accelerated the development of 
skin carcinoma [102]. In both animal models and human cancer tissues, it has been shown that VEGF is 
upregulated at both the mRNA and protein levels [103, 104]. During wound repair, there is a careful 
balance of pro- and anti-angiogenic factors at work. While new blood vessels are needed, the scales are 
tipped towards the pro-angiogenic factors. Following completion of the repair, however, the anti-
angiogenic factors, such as Thrombospondin-1 (TSP1) and the chemokine IP10, inhibit further blood 
vessel formation and act to arrest the process. In cancerous tissues, it is thought that angiogenesis 
proceeds uninhibited by both a continuous overexpression of pro-angiogenic factors, such as VEGF, as 
well as a disparate underexpression of anti-angiogenic factors [104]. Understanding the mechanisms by 
which angiogenesis occurs in cancer, as well as how the balance between pro- and anti-angiogenic 
factors is determined, may present viable targets for therapeutic intervention in the treatment of 
cancer. 
1.4.2 COX-2: An inducible mediator of inflammation 
One of the hallmark enzymes involved in inflammation is cyclooxygenase-2 (COX-2), an inducible 
isoform of an enzyme family responsible for the biosynthesis of prostaglandins and other prostanoids. 
COX-2 catalyzes the oxidation of arachidonic acid (AA) in a stereospecific manner into active mediators 
of inflammation, such as prostaglandin E2 (PGE2) and thromboxane (TXA) [105]. Figure 6 shows a simple 
schematic of arachidonic acid metabolism. During the 2-step oxidation process of AA, ROS are generated 
as a byproduct [106]. In primary cortical neurons, superoxide generated by COX-2 is responsible for 
increasing neuronal susceptibility to iron toxicity. This increase in toxicity can be reversed by co-addition 
of antioxidants or by pharmacological inhibition of COX-2 [107]. In the prostate, ROS is known to be 
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actively involved in stimulating EMT in cancer cells, and recent work by Giannoni et al. has shown that 
COX-2 is the primary source of ROS during CAF-mediated EMT in PCa cell lines. Again, this effect can be 
inhibited by either co-administration of antioxidants or by selective inhibition of COX-2 [108]. While 
oxidative stress signaling is clearly underlying these effects, in general antioxidants are less effective in 
blocking or reversing prostate pathology than inhibition of ROS generation at the source [109]. 
 
Figure 6. Schematic of arachidonic acid metabolism. Membrane phospholipids are liberated from the 
plasma membrane via the action of phospholipase A2 to provide arachidonic acid (AA). AA can be 
metabolized either by 5-lipoxygenase or cyclooxygenase (COX). As a byproduct of the enzymatic activity 
of COX-2, ROS are produced. 
 
Constitutively high levels of COX-2 are linked to tumorigenesis, decreased apoptosis, and cell-
cycle dysregulation, thus underscoring the importance of tightly controlling COX-2 expression and 
activity [106]. Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen are 
pharmacological inhibitors of the COX enzymes, and given the inducible nature of COX-2 in 
inflammation, specific COX-2 inhibitors have since been developed and approved for use [110]. There is 
epidemiological evidence to suggest that long-term NSAID use decreases the risk of colon cancer [111], 
but in prostate cancer results remain inconclusive [112, 113]. 
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In vitro analysis of PCa cell lines demonstrates a persistently elevated level of COX-2 expression, and 
this has been verified by tissue staining of PCa specimens showing elevated COX-2 presence in 
cancerous versus normal samples [86, 106]. Treatment of PC3 tumor-bearing mice with a selective COX-
2 inhibitor significantly reduces the tumor burden, indicating that high COX-2 expression by cancer cells 
may support continued proliferation [106]. Interestingly, however, it is not just COX-2 in the cancer cells 
that is necessary for its role in carcinogenesis. Xenografts of Lewis lung carcinoma cells into COX-2 null 
mice are unable to form tumors despite the presence of COX-2 in the cancer cells themselves. It was 
later demonstrated that stromal COX-2 is necessary for the production of the potent angiogenic factor, 
VEGF, and thus is an essential component to tumorigenesis [114]. Studies done on laryngeal squamous 
cell carcinoma have correlated stromal COX-2 expression with a worse cancer grade [115]. Clearly, COX-
2 plays a vital role in the development and progression of cancer. Specifically, stromal COX-2 is 
necessary for tumorigenesis and, as such, presents a viable target for therapeutic intervention. 
1.5 Goals of Dissertation 
The goals of this project are all directed at furthering our understanding of how the stromal 
microenvironment influences prostate cancer cell motility. I hypothesize that the prostatic stroma, 
irrespective of its activation state, maintains an intrinsic ability to limit cancer cell motility. However, 
cancer cells subvert this effect by increasing ROS production in neighboring myofibroblasts. In testing 
this hypothesis, I have pursued 3 main goals: 
1. To determine how a differential stromal response to locally produced TGFβ determines the 
redox status of the microenvironment 
2. To understand how the redox status of the local milieu directly affects the cancer cells’ ability to 
respond to stromal-produced paracrine factors 
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3. To identify the mediator responsible for the inherent ability of reactive prostate stromal cells to 
limit PCa cell motility in the absence of oxidative stress signaling 
The delicate interplay of all of these factors undoubtedly contributes to the complicated nature of 
therapy-resistant prostate cancer. To date, no one has suggested that a phenotypically 
transdifferentiated stroma maintains its inherent inhibition of PCa cell motility; this project addresses 
the novel concept that the prostatic stroma, irrespective of its “activation state,” maintains an 
intrinsic capacity to limit cancer cell motility through a local endocrine network . Adjacent cancer cells 
however, subvert this network through enhancement of ROS generation in the stromal cells. Thus, 
future therapeutic interventions should consider the gene set signature of both the cancer and 
surrounding microenvironment, as the balance of paracrine mediators between the two may 
ultimately determine the potency and efficacy of a drug for the treatment of PCa. 
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2.0 MATERIALS AND METHODS 
2.1 Chemicals and Reagents 
Recombinant human TGF-β1 and TGF-β1 neutralizing antibody were purchased from R&D systems 
(Minneapolis. MN) and were reconstituted according to the manufacturer’s protocol.  PGE2 and catalase  
were purchased from Sigma-Aldrich (St. Louis, MO). Amicon Ultra-4  centrifugal filter devices for 
fractionating conditioned media were purchased from Millipore (Billerica, MA). 4-hydroxytamoxifen and 
PHTPP were purchased from Tocris Bioscience (Ellisville, MO). 3β-Adiol was purchased from Sigma-
Aldrich (St. Louis, MO). Antibodies against ERβ were purchased from Millipore (Billerica, MA), Genetex 
(Irvine, CA), and Calbiochem (San Diego, CA).  An additional ERβ antibody was a gift from the lab of 
Benita Katzenellenbogen (University of Illinois, Urbana) [116]. Antibodies against E-cadherin, Smad 2/3 
and Smad 4 were purchased from Cell Signaling Technology (Danvers, MA). Fluorophore-tagged 
secondary antibody was purchased from Molecular Probes (Eugene, OR). Antibody against β-actin and 
secondary HRP-conjugated antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  
HTS Transwell 24-well plate inserts (3.0 µm pore size) were purchased from Corning Incorporated 
(Corning, NY). 
2.2 Cell culture 
WPMY-1, PS30, and DU145 cell lines are commercially available and were purchased from American 
Type Culture Collection (Rockville, MD). SH4 cells were generated as described below. Primary cultures 
PC116118 and PC115116 were obtained from radical prostatectomy specimens through UPCI. The cells 
were maintained in monolayer at 37⁰C in a 5% CO2 incubator in RPMI-1640 supplemented with 5% FBS 
and 1% penicillin/streptomycin. Cells were routinely passaged at a confluence of ~90%. 
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2.3 Transient Transfection 
Cells were transfected using Lipofectamine LTX with Plus Reagent (Invitrogen, Carlsbad, CA).  WPMY-1 
and PS30 cells were plated at ~70% confluency in a 12-well plate and grown overnight in antibiotic-free 
RPMI-1640 media with 5% FBS. The following day, per well amounts of  0.5 µg 3TP-lux, 0.1 µg Renilla-
luc, and 0.5 µL Plus reagent were incubated in opti-mem for 5 min. 1.5 µL LTX reagent was added, and 
the complex was incubated at room temperature for 30 min. The mixture was then added to the cells 
dropwise and incubated overnight. The following day cells were serum-starved for ~2h followed by 
treatment with TGF-β1 (0, 1, 2 ,5, 10 ng/mL). Cells were lysed in passive lysis buffer (Promega, Madison, 
WI), and the dual-injector luminometer Lumat LB 9507 (Berthold Technologies, Wildbad, Germany) was 
used to record both firefly and Renilla luciferase relative light unit (RLU) values. Firefly luciferase values 
were normalized to Renilla. 
2.4 Western blotting 
Whole cell lysates were prepared by lysing WPMY-1 cells in RIPA buffer (50mM Tris,150 mM NaCl, 0.1 % 
SDS, 0.5% Na Deoxycholate, 1 % Triton X 100). 15 µg total protein was run on a 10% acrylamide gel and 
transferred to a nitrocellulose membrane using a Transblot SD Semi-Dry transfer apparatus (Bio-Rad, 
Hercules, CA). Membranes were blocked 1h room temperature in 5% non-fat dry milk in PBS containing 
0.1% tween (PBS-T). The indicated antibody was added to a solution of 5% BSA/PBS-T in a concentration 
of 1:1000 and incubated overnight at 4⁰ with gentle rocking. Membranes were washed for 5 min 3x in 
PBS-T and then incubated with HRP-conjugated secondary antibody in a concentration of 1:3000 for 30 
min at room temp. Membranes were washed in PBS-T an additional 3 times, and enhanced 
chemiluminescence reagents were used to detect the HRP signal.  
Fractionation of lysates into nuclear and cytoplasmic fractions was carried out using according to the 
following protocol. Briefly, cells were trypsinzed and centrifuged at 1000 rpm for 4 min. The pellet was 
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washed once with PBS and re-pelleted. It was re-suspended in buffer (10 mM HEPES, 1.5 mM MgCl2, 10 
mM KCl, 0.5 mM DTT, protease inhibitors) and incubated on ice for 5 min. Cells were lysed using a pre-
chilled Dounce homogenizer. Dounced cells were centrifuged at 1000 rpm for 4 min to pellet nuclei, and 
the supernatant was retained as the cytoplasmic fraction. The nuclear pellet was resuspended in S1 
solution (0.25M sucrose, 10 mM MgCl2, protease inhibitors), and this was layered over an equal volume 
of S3 solution (0.88M sucrose, 0.5 mM MgCl2, protease inhibitors).  The suspension was centrifuged at 
3500 rpm for 10 min at 4⁰C. To prepare the cytoplasmic lysate, 1/5 total volume of 5X RIPA buffer was 
added and the samples were centrifuged at 3500 rpm for 10 min at 4⁰C. The nuclear pellet was 
resuspended in 1X RIPA buffer and centrifuged at 3500 rpm for 10 min at 4⁰C. The separate nuclear and 
cytoplasmic fractions were then subjected to a western blot as detailed above. 
2.5 Immunofluorescent staining 
DU145 cells were plated on coverslips at ~50% confluency and grown overnight. The following day the 
media was changed to either fresh 1% serum media or WPMY-1 CM and the cells were grown an 
additional 24h. Cells were then washed once in PBS and fixed to the slides using a 4% paraformaldehyde 
solution, followed by permeabilization with PBS/Triton-X (0.1%).  Two additional PBS washes were 
performed, and then the cells were blocked using Superblock (ScyTec Laboratories, Logan, UT). Cells 
were washed twice with PBS and then incubated overnight at 4⁰ with E-cadherin antibody in PBS 
(1:1000). The following day additional PBS washes were performed, a FITC-conjugated secondary 
antibody (1:300) and DAPI nuclear stain (1:10,000) were added, and coverslips were mounted on slides 
using Vectashield mounting medium (Vector Laboratories, Burlingame, CA).  
2.6 Generation of stable knockdown lines 
A lentivirus set containing 5 unique shRNA sequences specific for Cox-2 (Homo sapiens prostaglandin-
endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (PTGS2)) was purchased 
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from UPCI Lentiviral Core Facility (Pittsburgh, PA). WPMY-1 cells were seeded at 50% confluency in 
Optimem and grown overnight. The following day the media was replaced with fresh Optimem 
containing lentivirus and a final concentration of 8µg/mL polybrene. Cells were incubated ~18h at 37⁰C, 
and the following day the media was replaced with fresh RPMI-1640 containing 10% FBS. On day 3 after 
the infection, cells were passaged through a selection media containing 2 µg/mL puromycin for 5 days. 
Viable cells were expanded and a quantitative real-time PCR experiment was performed to confirm 
knockdown of COX-2 mRNA. The cell population demonstrating the greatest viability and knockdown 
were named SH4. 
2.7  Indirect co-culture wound healing assay 
Prostate stromal cells were plated in 6-well dishes at a density of 3X105 cells/well and grown overnight. 
Prostate epithelial tumor cells DU145 were seeded on coverslips in 6-well plates at a density of 2.5X105 
cells/well and grown overnight. The following day, the stromal cells were placed in serum free media 
(RPMI-1640 + 1%pen/strep) for ~2 hrs. The epithelial cells were scratched using a 200 µL pipette tip and 
the coverslip was then transferred cell-side up to the stromal cell containing well. The media was 
immediately replaced with RPMI-1640 + 1% FBS + 1% pen/strep and, when indicated, catalase was used 
at a final amount of 1500 units/mL. The wound was imaged at time zero. The co-culture system was 
incubated and the same areas were then imaged at time 24 hrs. The denuded zone was measured at 
time zero and again at time 24 hrs, and the percent wound closure was calculated by subtracting the 0 
hr wound size from the 24 hr wound size and multiplying by 100. TGF-β1 neutralizing antibody was used 
at a final concentration of 10 μg/mL.  
2.8 Conditioned Media 
Stromal cells were plated at the same density as the indirect co-culture assay and grown overnight. The 
following day they were serum starved for ~2 hrs and then the media was replaced with fresh media 
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containing 1% serum. Where indicated, exogenous TGF-β1 was added when indicated at a final 
concentration of 5 ng/mL. The cells were incubated overnight and the media was collected the following 
day, centrifuged at 1500xg for 3 minutes, and stored at -20⁰C. Prior to column fractionation, media was 
syringe filtered. The ultrafiltrate was diluted into fresh serum-free media, and the lower filtrate was 
used without any additional dilutions.   
Conditioned media was thawed and placed on freshly wounded naïve DU145 cells, and the wounds 
were imaged at time zero and time 24h. Wound closure was calculated as described above. Where 
indicated, H2O2 was added to conditioned media at final concentrations of 5, 10, and 20 µM prior to its 
use in the wound healing assay. 
2.9 RNA isolation, reverse transcription, and real-time PCR 
WPMY-1 prostate stromal cells were plated in 6-well plates at a density of 2.5x105 cells/well and were 
grown overnight. The following day they were placed in serum-free media and were serum starved for 
~2 hrs. TGF-β1 (0, 2, 5, 10 ng/mL) was then added and the cells were incubated overnight. WPMY-1 cells 
from co-culture were grown in the lower chamber of a transwell system and co-cultured in 1% FBS 
RPMI-1640 media for 24 hrs with a DU145 containing insert. The following day the media was removed, 
the cells were washed in sterile 1x PBS, and harvested in 500 μL cold Trizol. RNA was extracted using the 
RNeasy kit from Qiagen (Valencia, CA) and was quantified on the Nanodrop ND-1000. cDNA was 
synthesized using the iScript kit from Bio-Rad (Hercules, CA) according to the kit protocol, and the final 
product was diluted to a total volume of 100μL using nuclease-free water. Quantitative real-time PCR 
was performed using the iTaq Sybr green kit from Bio-Rad (Hercules, CA). Table 1 shows the primer 
sequences that were used.  Samples were run through an initial denaturation step of 95⁰ for 10 min 
followed by 40 cycles of 95⁰ for 30s, 55⁰ for 1 min, and 72⁰ for 1 min.  Relative expression was 
determined using the comparative Ct method. 
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Table 1. Primer sequences used in qRT-PCR 
Gene Forward Reverse 
Cox-2  5’-ATCACAGGCTTCCATTGACC-3’ 5’-CAGGATAGAGCTCCACAGCA-3’ 
E-cadherin 5’-TGAAGGTGACAGAGCCTCTGGAT-3’ 5’-TGGGTGAATTCGGGCTTGTT-3’ 
GAPDH 5’-TTGCCATCAATGACCCCTTCA-3’ 5’-CGCCCCACTTGATTTTGGA-3’ 
 
2.10 Chromatin Immunoprecipitation (ChIP) 
DU145 cells were grown to ~80% confluence on 15cm plates and treated for 18h with either control or 
WPMY-1 CM -/+ H2O2 (10µM). The following day, media was replaced with fresh complete growth 
medium (5% FBS) containing 1% formaldehyde for cross-linking. Cells were incubated at 37⁰ for 20 min, 
followed by addition of glycine and an additional 10 min incubation at room temperature. Cells were 
washed once in 1x PBS, then collected in ice-cold 1x PBS containing protease inhibitors. Cells were 
pelleted at 2000 rpm for 10 minutes at 4⁰. PBS was discarded and cells were resuspended in lysis buffer 
containing protease inhibitors. Following a 15 min incubation on ice, cells were sonicated at maximum 
setting using a bioruptor with 30 sec on/off pulses for 10 min. Cells were incubated on ice 5 min, and an 
additional 5 min of sonication was performed. A DNA gel was run to ensure adequate shearing of the 
chromatin to approximately 1 kb fragments. Sheared chromatin was diluted in ChIP dilution buffer 
containing protease inhibitors to a final concentration of 250 µg/mL. Antibodies were linked to anti-
mouse IgG magnetic beads in low-salt immune complex buffer for 6 hrs at 4⁰. Anti-ERβ antibodies were 
used at a final concentration of 2 µg/mL. During antibody linking, chromatin samples were precleared 
using fresh magnetic beads, and a portion of this precleared sample was used as input sample. The 
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remaining precleared chromatin was then incubated overnight at 4⁰ with the antibody-linked beads. The 
following day, beads were washed for 15 min 1x each with low salt immune complex buffer, high salt 
immune complex buffer, LiCl immune complex buffer, and 1x TE buffer. After the final wash, beads were 
resuspended in 150 µL TE for a final rinse before addition of 400 µL elution buffer. Proteinase K (5 µL) 
was added to each sample and they were incubated overnight at 65⁰. The following day DNA was 
extracted using phenol:chloroform:isoamyl alcohol (25:24:1). Glycogen (2 µL) and sodium acetate (35 
µL) were added and samples were vortexed, followed by addition of 800 µL ice-cold ethanol. Samples 
were incubated at -20⁰ 1-2 hrs and then centrifuged at 13,000 rpm for 60 min at 4⁰. Pellet was washed 
once with 70% EtOH, respun, and pellet was allowed to air dry on ice for 2 hrs. Pellet was resuspended 
in 30 µL RNase-free water, and the DNA was then subjected to quantitative real-time PCR analysis 
(described above). Table 2 below lists the primers used for 3 different ERβ binding sites within the E-
cadherin promoter.  RT-PCR results were calculated using the Ct method and are presented as assay 
site IP fold enrichment. 
Table 2. Primer sequences for ERβ binding sites within the E-cadherin promoter 
Site Forward Reverse 
1 5’-GACCTGAGACCTTTGGCCCCTA-3’ 5’-TATCTCCTCTTGGCGAACTTGG-3’ 
 
2 5’-CAATCAGCGGTACGGGGGGCGG-3’ 5’-GGTTCTTTCCAGCATTTATCCT-3’ 
3 5’-CCGGTTCCATCTACCTTTCCCC-3’ 5’-GAACCAATGACCCGACACCGAA-3’ 
 
2.11 Measurement of ROS Production 
WPMY-1 cells were plated at a density of 3000 cells/well in black-walled clear bottom 96-well tissue 
culture plates (Greiner Bio-One, Radnor, PA) in phenol-red free RPMI-1640 containing 5% FBS. The 
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following day, cells were serum starved for ~90 min and TGFβ was added in fresh serum-free media. The 
cells were incubated for 3h and H2O2 production was measured using an Amplex Red Enzyme Assay 
(Invitrogen, Carlsbad, CA). 
2.12 Imaging and Densitometric Analysis 
All images were obtained on an Olympus IX71 inverted microscope (Olympus, Center Valley, PA). 
Western blot films were electronically scanned and the images were analyzed using Image J software 
(open sourced through the NIH). 
2.13 Statistical Analysis 
Two-sample comparisons were performed using the Student t test. Multiple comparisons were 
performed using a one-way ANOVA followed by the Tukey test or a two-way ANOVA followed by a 
Bonferroni posttest. All data are represented  SEM and are representative of ≥ 3 independent 
biological replicates. p values < .05 are considered significant.   
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3.0 RESULTS 
3.1  TGF-β1 signaling in reactive human prostate stromal cells overrides 
their inherent motility inhibitory activity towards co-cultured PCa cells 
 It has been previously established that co-culturing non-cancerous immortalized prostate 
epithelial cells with cancer-associated fibroblasts (CAFs) leads to malignant transformation and tumor 
development in a xenograft mouse model [3, 64, 117]. To test the impact of indirect co-culture with 
CAFs on the motility of a prostate cancer cell line, I used a modified wound healing assay as previously 
described [118]. It is important to note that in this assay the stromal and cancer cells are not in direct 
contact, but they do share a common growth medium.  
In addition to using 2 primary CAF cultures (PC116118 and PC115116), I also chose 2 established 
and well-characterized prostate stromal cell lines. The WPMY-1 line is myofibroblastic and thus imitates 
a CAF-like phenotype, whereas the PS30 line is derived from the immortalization of normal prostatic 
fibroblasts. The cancer cell line that I chose for my experiments is the DU145, which is a highly 
aggressive and motile cell line derived from a distant metastatic site. Of particular interest is that the 
DU145 line overproduces TGF-β1, yet itself has become immune to the growth suppressive effects TGF-
β1 exerts on normal prostatic epithelium. 
As Figure 7 demonstrates, both primary CAFs and the myofibroblastic cell line WPMY-1 are 
permissive of DU145 motility in indirect co-culture. In low-serum containing conditions, DU145 cells 
growing at near confluence can close a constant diameter wound approximately 22% in 24 hrs. This 
wound closure is not significantly altered by co-culture with either CAFs or WPMY-1 cells, but it is 
significantly inhibited by the presence of PS30 cells. To exclude the influence of proliferation on this 
wound closing effect, the doubling time of DU145 cells under these same low-serum conditions was 
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determined to be approximately 40 hrs. Thus, at 24 hrs the most significant contributor to wound 
closure is the movement of existing cells into the denuded zone. 
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Figure 7.  Indirect co-culture with CAFs and WPMY-1 cells is permissive of inherent DU145 motility 
In a modified wound healing assay, DU145 motility is unaffected by the presence of CAFs (PC116118 and 
PC115116) or WPMY-1 cells, but is significantly reduced by PS30 cells. Data represent the mean  SEM 
from 3 independent experiments, each repeated in technical triplicate.  A one-way ANOVA followed by 
Tukey’s multiple comparison test was performed.*p<.05 compared to respective DU145 control. 
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Since DU145 cells secrete high levels of active TGF-β1, I hypothesized that the discrepancy of 
myofibroblastic and fibroblastic stromal cells on DU145 motility was due to a differential response to 
locally produced TGF-β1. To assess if there was an inherent difference in response to TGF-β1, the 
WPMY-1 and PS30 lines were employed as models to represent a myofibroblast and a fibroblast, 
respectively, and a measurement of the transcriptional activity of a TGFβ-response element (3TP-lux) 
following stimulation with exogenous TGF-β1 was performed. WPMY-1 and PS30 cells were transiently 
co-transfected with the Smad-binding element luciferase construct (3TP-lux) and Renilla luciferase 
(Renilla-luc). The cells were then treated with various concentrations of TGF-β1, and cell extracts were 
analyzed for luciferase activity. Figure 8 demonstrates that at all concentrations of TGF-β1, WPMY-1 
cells exhibit a significantly more robust transcriptional response than the PS30 cells. 
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Figure 8.  WPMY-1 cells exhibit a more robust transcriptional response to exogenous TGF-β1 
treatment.  
WPMY-1 and PS30 cells were transiently co-transfected with the 3TP-lux-luciferase (luc) reporter and 
Renilla-luc overnight, then subjected to a 6h TGF-β1 treatment the following day (0, 1 , 2, 5 10 
ng/mL). Cells were lysed and firefly luc activity was measured and normalized to Renilla luc activity. 
Data represent the mean  SEM of 3 independent experiments, each performed in triplicate. A two-
way ANOVA followed by Bonferroni posttest was performed. ***p<.001 
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To further test whether WPMY-1 cells possess a more active TGFβ response pathway, a western 
blot analysis of whole cell lysates was performed to determine the level of Smad proteins in WPMY-1 
and PS30 cells. Figure 9a is a representative blot of 2 independent samples from each cell type. 
Densitometric analysis of the blots reveals that WPMY-1 cells contain significantly more Smad 3 and 
Smad 4 protein than PS30 cells (Figure 9b). This is in accordance with the observation that WPMY-1 cells 
have a more robust response to TGF-β1. 
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Figure 9.  WPMY-1 cells express higher levels of Smads 3&4 
Untreated WPMY-1 and PS30 cells were lysed in cold RIPA buffer and subjected to western blot 
analysis for Smads 2,3, and 4. (A) A representative blot is shown, and (B) a graphical display of 
densitometric analysis representing the mean  SEM of 3 independent experiments is 
presented. A 2-way ANOVA followed by a Bonferroni posttest was performed. *p<.05 
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To uncover the role of TGFβ signaling in modulating stromal cell regulation of PCa cell motility,  
an interfering TGF-β1 antibody was used in co-culture assays. The upper panel (Figure 10a) shows 
representative images from the wound healing assay taken at zero and twenty-four hours. Quantitation 
of multiple repeats is shown in graphical form in Figure 10b, and these results demonstrate that 
inhibition of TGFβ signaling did not affect the inherent motility of DU145 cells but uncovered an 
inherent motility inhibitory activity of the WPMY-1 cells. The motility inhibitory activity of the PS30 cells 
was not affected by the TGF-β1 neutralizing antibody. These results suggest that while TGF-β1 does not 
affect DU145 cell movement, it is required for reactive stromal cells to obtain their permissive effect on 
cancer cell motility. Additionally, these data suggest that while both reactive and non-reactive prostate 
stromal cells produce an inherent cancer cell motility inhibitory factor (hereafter referred to as stromal-
derived motility inhibitory factor, SMIF), reactive stroma respond to TGF-β1 produced by cancer cells to 
limit either the production or activity of SMIF.  
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 Figure 10. Locally produced TGF-β1 is necessary for the permissive effect of WPMY-1 cells on DU145 
motility. 
WPMY-1 cells are permissive of the highly motile phenotype of DU145 PCa cells; PS30 cells inhibit 
DU145 motility in co-culture. Addition of a TGFβ1-neutralizing antibody blocks the permissive effects of 
co-cultured WPMY-1 cells on PCa cell motility, but does not affect motility when added to DU145 cells 
alone or in co-culture with PS30 cells. (A) The upper panel is representative images from the modified 
wound healing assay. (B) Data represent the mean  SEM from 4 independent experiments, each 
repeated in technical triplicate.  A one-way ANOVA followed by Tukey’s multiple comparison test was 
performed.*p<.05 compared to respective DU145 control. ** p< .01 relative to DU145 treated with 
TGFβ neutralizing antibody. 
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As a direct test to determine if TGF-β1 limits the production of SMIF, conditioned media (CM) 
was isolated from WPMY-1 cells grown overnight in 1% serum-containing media with or without 
exogenous TGF-β1 (5 ng/mL) and added to freshly wounded naïve DU145 cells. Surprisingly, CM from 
WPMY-1 cells treated with exogenous TGF-β1 significantly inhibited DU145 motility (Figure 11). Thus, 
TGF-β1 does not inhibit the production of SMIF, but rather blocks its activity when present in co-culture. 
Because the inhibitory activity is transferrable in CM, the effect of TGF-β1 on SMIF activity is likely 
mediated through a short-lived molecule. 
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Figure 11. Inhibition of DU145 motility is transferrable in WPMY-1 CM irrespective of TGF-β1 
treatment 
WPMY-1 cell CM was obtained following overnight growth in 1% serum media -/+ TGF-β1 (5 
ng/mL). Naïve DU145 cells were wounded and media replaced with WPMY-1 CM. Wound closure 
over 24h was determined. Data represent the mean  SEM from 3 independent experiments, 
each repeated in technical triplicate. A one-way ANOVA followed by Tukey’s multiple comparison 
test was performed. ** p< .01 compared to control media 
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As an additional test of the effect of CM on DU145 motility, naïve DU145 cells were treated with 
either control or WPMY-1 CM and then subjected to Western blot analysis for the adhesion molecule E-
cadherin. PCa cells undergo full or partial epithelial-to-mesenchymal transition (EMT) and thus lose 
expression of the epithelial marker E-cadherin. A loss of E-cadherin is associated with a decrease in cell 
adhesion and a subsequent increase in motility. As Figure 12 shows, CM significantly enhanced 
expression of E-cadherin, consistent with partial reversal of EMT and hence a decrease in cell motility. 
Additionally, immunoflourescence staining for E-cadherin was also performed. Figure 13 displays 
representative images from immunofluorescent staining showing increased E-cadherin staining along 
the cell membrane in DU145 cells following overnight incubation with CM.  
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Figure 12. WPMY-1 CM induces E-cadherin expression in DU145 cells 
Western blot of whole cell lysate from DU145 cells cultured in WPMY-1 CM for 24 hrs reveals a 
significant increase in protein levels of the cell adhesion molecule E-cadherin. (A) The upper panel is 
a blot representative of 3 biological replicates (B) A graphical summary of the densitometric analysis 
of E-cadherin expression normalized to β-actin used as a loading control. Bars represent the mean of 
3 independent experiments  SEM. A t-test was performed to determine significance. *p<.05 
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Figure 13. WPMY-1 CM induces E-cadherin staining in DU145 cells. 
DU145 cells were grown in WPMY-1 CM for 24 hrs, fixed in 4% paraformaldehyde, and stained for E-cadherin. 
DAPI was used as a nuclear stain, and DAPI and FITC fluorescence were recorded and overlayed. Control cells 
display a diffuse cytoplasmic pattern for E-cadherin, while CM treatment results in a more intense cytoplasmic 
staining for E-cadherin which is concentrated at the cell membrane, consistent with increased adhesion. 
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3.2  ROS generated following TGF-β1 signaling overrides the 
inherent motility inhibitory activity of WPMY-1 cells  
ROS are known to be active mediators of the TGFβ-driven transdifferentiation into 
myofibroblasts [119], and recent work has shown that expression of NADPH oxidase 4 (NOX4), an H2O2-
generating enzyme, is necessary for the apoptotic effects of TGF-β1 on pulmonary epithelial cells [120]. 
Clearly TGFβ and ROS production are intimately related; thus, I next turned my focus to investigating 
ROS as a potential short-lived mediator of the TGFβ-dependent effect on SMIF activity in co-culture. 
Hydrogen peroxide is one ROS ultimately generated in response to TGF-β1 that can participate in local 
paracrine signaling. While H2O2 is not typically considered a very short-lived molecule, antioxidant 
defenses within the cancer cells could potentially neutralize H2O2 if it is not constituitively being 
produced; thus, CM may contain small amounts of H2O2, but in the absence of chronic production as in 
co-culture, the H2O2 is neutralized before it exerts a measurable effect on the cancer cells. To examine 
whether TGF-β1 activates an oxidant signaling pathway in WPMY-1 cells, an Amplex Red endpoint assay 
was performed to measure H2O2 production. As Figure 14 shows, a 3h TGF-β1 treatment significantly 
increased production of H2O2 at both 2 and 5 ng/mL doses.   
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Figure 14. Addition of TGF-β1 to WPMY-1 cells increases H2O2 production. 
In response to exogenous TGF-β1, WPMY-1 cells produce increased levels of H2O2 as measured by an 
endpoint Amplex Red assay. WPMY-1 cells were serum starved for 90 min before addition of TGF-β1 
in fresh serum free media. Cells were incubated with the TGFβ for 3h, Amplex Red was added to cell 
cultures, and an endpoint fluorescence reading was recorded at 1h. Data represent mean from 3 
biological replicates   SEM. A one-way ANOVA followed by Tukey’s multiple comparison test was 
performed. * p<.05, ** p< .01 relative to untreated WPMY-1 control 
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A TGF-β1-dependent increase in  H2O2 suggests that it may be a viable candidate for the non-
transferrable inhibitor of SMIF. Therefore, wound healing assays were performed with the addition of 
catalase (1500 units/mL), a cell impermeant enzyme that metabolizes H2O2 to H2O and O2. I again 
included the primary stromal cultures to confirm that H2O2 was responsible for the permissive effect of 
the CAF phenotype.  As Figure 15 shows, while addition of catalase did not alter the inherent highly 
motile phenotype of the DU145 cells, it reversed the permissive effect of WPMY-1 and CAFs and 
restored the activity of SMIF when added to DU145/CAF and DU145/WPMY-1 co-cultures. Therefore, 
extracellular H2O2 is necessary for WPMY-1 and CAFs to override the inherent activity of SMIF and 
support the efficient motility of co-cultured DU145 cells. Importantly, extracellular H2O2 does not 
regulate the inherent motility capacity of DU145 cells. 
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 Figure 15. Addition of catalase to co-cultures reverses the permissive role of CAFs and WPMY-1 cells 
on DU145 motility 
The modified wound healing assay was performed with the addition of 1500 units of catalase per 1 mL 
of media. Data are representative of 3 independent experiments  SEM. A one-way ANOVA followed by 
Tukey’s multiple comparison test was performed. * p< 0.05 comparing control co-culture to co-culture 
with the addition of catalase. 
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Since PS30 cells are less responsive to TGF-β1, it can be inferred that they lack the increased 
ROS production following TGF-β1 stimulation that is seen in the myofibroblastic WPMY-1 cells. The 
addition of catalase neutralized H2O2 in the CAF and myofibroblastic co-cultures and led to a restoration 
of SMIF activity. Thus, to further confirm a role for extracellular H2O2 as a negative regulator of SMIF 
activity, exogenous H2O2 (10 µM) was added to DU145/PS30 co-culture to test whether the SMIF activity 
was inhibited upon introduction of oxidative stress signaling. As expected, addition of H2O2 to 
DU145/PS30 co-culture significantly increased the motile capacity of the DU145 cells when compared to 
untreated co-culture conditions (Figure 16). This again suggests a crucial role for extracellular H2O2 in 
inhibiting the effect of SMIF on DU145 motility in co-culture.  
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Figure 16. Addition of H2O2 to DU145/PS30 co-culture reverses motility suppression of DU145 cells 
DU145 cells were co-cultured with PS30 cells as described previously under either control or H2O2-
containing (10 µM) conditions. A modified wound healing assay was performed and wound closure over 
24 hrs was calculated. Data represent mean  SEM of 3 independent experiments. A one-way ANOVA 
followed by Tukey’s multiple comparison test was performed. ** p<.01 
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3.3 Cox-2 is a predominant source of ROS in WPMY-1 cells 
Having confirmed the role of both TGF-β1 and H2O2 in modulating the activity of SMIF in co-
culture, I next sought to identify a source of ROS that is downstream of TGFβ signaling. Using a wound 
healing assay to assess biological function of SMIF, it was apposite to consider a variation of the normal 
wound healing process as underlying the observed effects thus far. In aberrant wound healing, excessive 
TGFβ is present [121]. Thus, in the wound healing assay, I hypothesized that the mobilization of redox 
signaling pathways is utilized by TGF-β1 to influence paracrine communication. That is, TGF-β1 induces 
the expression of enzymes such as COX-2 and some NOX isoforms that generate ROS. In DU145/WPMY-
1 co-cultures, COX-2 mRNA was induced in WPMY-1 cells as revealed by quantitative real-time PCR. TGF-
β1’s role in this induction was confirmed by inclusion of a TGF-β1 neutralizing antibody, which abolished 
the COX-2 mRNA induction in co-cultured WPMY-1 cells (Figure 17). 
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 Figure 17. Co-culture with DU145 cells increases levels of COX-2 mRNA transcript in WPMY-1 cells  
A transwell insert containing DU145 cells was placed into a chamber containing serum-starved WPMY-1 
cells, and the media was replaced with fresh 1% serum-containing RPMI -/+ a TGFβ neutralizing antibody. 
Control cells were incubated with an empty insert. The cells were co-cultured for 24h and the WPMY-1 cells 
from the lower chamber were collected in Trizol and subject to reverse transcription and quantitative real-
time PCR for COX-2 transcript levels. Data represent the mean  SEM from 3 independent experiments. A 
one-way ANOVA followed by Tukey’s multiple comparison test was performed.* p < .05 relative to control 
and TGFβ neutralizing antibody. 
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 To determine to what extent stromal-derived COX-2 is involved in producing ROS that have an 
impact on cancer cell motility in co-cultures, a pharmacologic selective COX-2 inhibitor, NS398, was used 
in co-cultures. However, NS398 significantly decreased inherent DU145 motility due to the expression of 
COX-2 in the DU145 cells (data not shown). Thus, this approach proved ineffective at isolating the 
specific role of stromal COX-2.  In order to understand the contribution of stromal COX-2, a recombinant 
lentiviral vector system expressing a specific COX-2 shRNA (SH4) sequence was used to generate a stable 
WPMY-1 variant line lacking inducible COX-2. A control vector expressing a scrambled shRNA (Scr) 
sequence was also stably expressed in a different variant line. This approach allowed for the selective 
knockdown of COX-2 in stromal cells in co-culture while leaving DU145 COX-2 unaffected. As basal levels 
of COX-2 mRNA are very low in WPMY-1 cells, the efficiency of the knockdown was analyzed via qRT-
PCR following treatment of WPMY-1 or SH4 cells with 5 ng/mL TGF-β1. As Figure 18 shows, TGF-β1 
induction of COX-2 mRNA was reduced 65% in SH4 cells relative to WPMY-1. 
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Figure 18. Stable knockdown of COX-2 in WPMY-1 cells 
A lentiviral vector expressing shRNA directed against COX-2 (SH4) was used to stably infect WPMY-1 
cells. Following selection through puromycin and clonal expansion, the resulting lines were subjected 
to a 24h treatment with TGFβ in serum-free media (5 ng/mL) and COX-2 mRNA levels determined by 
quantitative RT-PCR. Fold change over untreated controls was determined. Data represent 3 
independent experiments  SEM. A one-way ANOVA followed by Tukey’s multiple comparison test was 
performed. *p<.05 
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 Since extracellular H2O2 is necessary for inhibition of SMIF activity, we sought to determine if 
COX-2 plays a significant role in the generation of H2O2. Given that previous work has shown that COX-2 
can be a significant source of ROS generation [107], SH4 cells were subjected to an endpoint Amplex Red 
assay identical to the one performed on WPMY-1 cells in Figure 14. As Figure 19 shows, TGF-β1 is unable 
to produce a significant increase in H2O2 production in WPMY-1 cells lacking inducible COX-2. This is in 
contrast to the wild-type WPMY-1 cells, which respond to TGF-β1 with a significant increase in H2O2 
production (see Figure 14). This suggests that COX-2 is at least partially responsible for the TGF-β1 
induced increase in H2O2 production. 
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Figure 19. TGF-β1 does not induce H2O2 production in SH4 cells 
In response to exogenous TGF-β1, SH4 cells lack an increase in H2O2 production as measured by an 
endpoint Amplex Red assay. SH4 cells were serum starved for 90 min before addition of TGF-β1 in 
fresh serum free media. Cells were incubated with the TGFβ for 3h, Amplex Red was added to co-
cultures, and an endpoint reading was recorded at 1h. Data represent mean from 3 biological 
replicates   SEM. 
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 Of interest next was to determine if knockdown of COX-2 altered the TGF-β1-dependent 
inhibition of SMIF in WPMY-1 cells. This is of particular relevance since other ROS-generating enzymes 
are responsive to TGF-β1 in WPMY-1 cells. As shown in Figure 20, DU145 motility is inhibited when co-
cultured with SH4 cells. This is in contrast to WPMY-1 and Scr cells, which are permissive for DU145 
motility in co-culture. Importantly, the degree of motility inhibition between DU145/WPMY-1 co-culture 
with catalase and DU145/SH4 co-culture is not significantly different, indicating that ablation of COX-2 is 
sufficient to reduce H2O2 levels to an extent that restores SMIF activity. To further confirm that stromal 
COX-2 is a significant source of TGF-β1 inducible H2O2 in WPMY-1 cells, catalase (1500 units/mL) was 
included in co-culture scratch assays. Figure 20 shows that the addition of catalase does not further 
accentuate the inhibitory activity of SH4 cells on DU145 motility in co-cultures. Therefore, WPMY-1 cells 
in which TGF-β1 induction of COX-2 expression and subsequent H2O2 production is limited (SH4 cells) 
acquire the characteristics of non-reactive stroma to limit DU145 motility in co-culture. Additionally, 
COX-2 is the predominant source of TGF-β1 inducible H2O2 in WPMY-1 cells that is responsible for 
limiting the activity of SMIF. 
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Figure 20. COX-2 is the predominant source of H2O2 responsible for WPMY-1 cells’ permissive effect on 
DU145 motility 
Addition of catalase to co-cultures reverses the permissive role of Scr cells in DU145 motility but does 
not further accentuate the motility inhibition offered by the SH4 cells. The modified wound healing 
assay was performed with the addition of 1500 units of catalase per 1 mL of media. A one-way ANOVA 
followed by Tukey’s multiple comparison test was performed. * p< .05 relative to appropriate DU145 
control 
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3.4  Hydrogen peroxide produced by COX-2 in WPMY-1 cells 
modulates the response of DU145 cells to SMIF 
In the absence of chronic TGF-β1 stimulation in co-culture with DU145 cells, WPMY-1 cells 
produce an inhibitor of cancer cell motility (SMIF). This inhibitor is transferrable in conditioned media 
and accumulates when COX-2 is ablated in WPMY-1 cells. Thus, I hypothesized that stromal COX-2 was 
generating H2O2, and this was in turn modulating the effect of SMIF. To test whether H2O2 could alter 
the activity of SMIF, varying concentrations of H2O2 were added to CM from WPMY-1 cells. While a 
single bolus of H2O2 (5, 10, and 20 µM) does not significantly influence DU145 motility alone, H2O2 
addition concentration-dependently reversed the motility inhibitory activity of the WPMY-1 CM (Figure 
21).  
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Figure 21. Addition of H2O2 to CM inhibits the activity of SMIF on DU145 motility 
Conditioned media loses its inhibitory effect on DU145 motility at concentrations of H2O2 ≥ 10 μM. 
CM was generated as previously described from WPMY-1 cells. Naïve DU145 cells were wounded 
and the media was replaced with CM to which varying amounts of H2O2 had been added. Data 
represent the mean of 6 independent experiments  SEM. A one-way ANOVA followed by Tukey’s 
multiple comparison test was performed. **p<.01 relative to appropriate control media 
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To further examine whether it is H2O2 generated by stromal COX-2 is indeed necessary for 
inhibition of SMIF activity, exogenous H2O2 was added to DU145/SH4 co-cultures. Figure 22 shows that 
the inhibitory effect of SH4 cells on DU145 motility is lost when H2O2 is re-introduced to co-cultures. This 
suggests that TGFβ-dependent induction of COX-2 is necessary for H2O2 production in co-culture to limit 
the activity of SMIF. Additionally, when the major prostatic COX-2 metabolite PGE2 was added to co-
cultures, no significant change in motility was observed (data not shown), suggesting that COX-2-derived 
PGE2 is not involved in SMIF activity.  
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Figure 22. H2O2 generated by stromal COX-2 is necessary for inhibition of SMIF in co-culture 
Addition of H2O2 (10 μM) to the DU145/SH4 co-culture reverses the motility inhibition seen under basal 
conditions. A modified wound healing assay as previously described was carried out with and without 
the addition of H2O2. Data represent the results of 4 independent experiments  SEM. A one-way 
ANOVA followed by Tukey’s multiple comparison test was performed. * p<.05 relative to appropriate 
DU145 control 
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These results suggest that either SMIF is being oxidatively modified by H2O2, or that H2O2 
produced by WPMY-1 cells is influencing the response of the DU145 cells to the constitutively produced 
SMIF. To address this issue, CM was pre-treated with 10 μM H2O2 for 3h to allow potential oxidation of 
SMIF. Prior to treating wounded naïve DU145 cells with the CM, catalase (1500 units/mL) was added to 
neutralize the remaining H2O2. This was to ensure that SMIF had the opportunity to be oxidatively 
modified without exposing the DU145 cells to H2O2. As Figure 23 shows, pre-treatment of the WPMY-1 
CM with H2O2 did not alter its inhibitory effect on DU145 cell motility. As shown previously, continuous 
exposure of DU145 cells to CM and H2O2 reversed the motility suppression effect of CM alone. These 
results imply that the WPMY-1 cell produced SMIF is not being oxidized, but rather that H2O2 is acting 
directly on the DU145 cells’ response to SMIF. 
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Figure 23. H2O2 acts directly on the DU145 cells to inhibit their response to SMIF 
CM was incubated with 10 µM H2O2 for 3h. Following this pretreatment, a portion of the media 
was then treated with catalase (1500 units/mL) and the 2 different treatment groups were added 
to wounded naïve DU145 cells. Data represent 3 independent experiments  SEM. A one-way 
ANOVA followed by Tukey’s multiple comparison test was performed. * p<.05 compared to all 
other conditions 
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3.5  The motility inhibitory activity of WPMY-1 cells acts via ERβ in 
DU145 cells to modulate their motility 
The current data suggest that SMIF is constitutively produced by the stroma, regardless of a 
myofibroblastic phenotype. Rather, it is a loss of DU145 responsiveness to the action of SMIF as a result 
of local H2O2 production from an increased TGFβ responsiveness leading to an inflammatory milieu. The 
next step was to elucidate the identity of SMIF and further understand how H2O2 was preventing its 
action.  For an initial assessment of the identity of SMIF produced by WPMY-1 cells, a column 
fractionation technique was used to separate the components in the CM into high (>5 kD) and low (<5 
kD) molecular weight fractions. These separate fractions were then applied to naïve DU145 cells and 
their motility measured. As Figure 24 shows, the low molecular weight fraction retains the inhibitory 
activity present in intact WPMY-1 cell CM on DU145 cell motility. The high molecular weight fraction is 
permissive for DU145 motility and re-addition of the low MW fraction again restores the motility 
suppression observed with complete CM. 
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Figure 24. SMIF is present in the low molecular weight fraction of CM 
WPMY-1 CM was fractionated into high and low molecular weight fractions, and each fraction was 
tested independently for biological activity. The low molecular weight fraction (pore size <5kD) retains 
inhibitory effects on DU145 motility. Data are representative of 4 independent biological replicates  
SEM. A one-way ANOVA followed by Tukey’s multiple comparison test was performed, ***p<.001 
compared to both DU145 control and the high molecular weight fraction 
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In lieu of further purification of the CM 5 kDa and below fraction, we postulated that 2 
candidate potential low molecular weight inhibitors of cancer cell motility were involved. Two androgen 
derivatives, 5α-androstane-3α,17β-adiol (3α-Adiol) and 5α-androstane-3β,17β-adiol (3β-Adiol), whose 
molecular weights are both <5kD, have been found to increase cancer cell adhesion and decrease cell 
motility in an ERβ-dependent manner [58, 59]. These androgen metabolites do not bind AR but are 
potent ligands for ERβ [58]. DU145 cells express the ERβ isoform but no detectable ERα [46, 58, 59]. 
Therefore, to determine if this pathway was responsible for the oxidant-dependent inhibition of motility 
in co-culture, an examination of the impact of H2O2 on the motility inhibitory activity of exogenous 3β-
Adiol (10-6 M) was performed.  Consistent with previously published reports, 3β-Adiol suppressed DU145 
cell motility [58, 59]. Intriguingly, this inhibitory effect was reversed by H2O2 (Figure 25).  
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Figure 25. 3β-Adiol inhibits DU145 motility in an oxidation-sensitive manner 
Addition of exogenous 3β-Adiol (10-6 M) is able to significantly inhibit DU145 motility. This effect is 
reversed when 10 µM H2O2 is added to the media. Data are representative of 4 independent 
biological replicates  SEM.  A one-way ANOVA followed by Tukey’s multiple comparison test was 
performed. **p<.01 compared to all other conditions 
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To further investigate the role of ERβ in regulating the motility response of DU145 cells to 
WPMY-1 generated factors, tamoxifen, which acts as an ERβ antagonist, and the selective ERβ 
antagonist 4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP) were 
added to the wound healing assays. As Figure 26 shows, addition of both tamoxifen and PHTPP reverses 
the motility inhibitory effect of WPMY-1 CM. Thus, these data corroborate that the WPMY-1 produced 
SMIF acts on ERβ in DU145 cells to limit their motility. 
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Figure 26. SMIF acts on DU145 cells through ERβ 
Naïve DU145 cells were wounded and treated with either control or WPMY-1 CM with 4-
hydroxytamoxifen (10-7 M) or PHTPP (0.1 µM). Results are representative of 4 independent 
biological replicates  SEM. A one-way ANOVA followed by Tukey’s multiple comparison test was 
performed.  ***p<.001 compared to conditions containing control media p<.05 compared to CM  
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Previous work has shown E-cadherin to be a downstream target of ERβ signaling that is 
responsible for the decrease in motility seen with 3β-Adiol treatment [58]. I have already shown that 
WPMY-1 cell CM induces E-cadherin expression in DU145 cells but, importantly, I sought to determine if 
the addition of H2O2 to CM would reverse this effect. DU145 cells were treated with either control or CM 
-/+ H2O2 for 18 hrs, and qRT-PCR analysis was performed for E-cadherin expression. As Figure 27 shows, 
WPMY-1 cell CM significantly increased E-cadherin expression, which is lost when H2O2 (10 µM) is 
present. 
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Figure 27. Treatment with CM induces E-cadherin mRNA in DU145 cells in an oxidation-sensitive 
manner 
Naïve DU145 cells were treated for 18h with either control 1% serum media or WPMY-1 CM, -/+ 10 
µM H2O2. The cells were then harvested in Trizol and subjected to quantitative real-time PCR for E-
cadherin transcript levels. Results are indicative of 3 independent samples and are displayed  
SEM. A one-way ANOVA followed by Tukey’s multiple comparison test was performed. *p<.05 
relative to all other conditions 
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Various steps in ERβ signaling pathway were examined in order to uncover the mechanisms of 
H2O2 inhibition of E-cadherin mRNA expression. While most SR expression levels are decreased by 
chronic treatment with ligand, it has been suggested that estradiol (E2) positively regulates both ERα 
and ERβ expression [95]. Furthermore, ERα and ERβ expression have both been shown to be altered by 
oxidative stress, including administration of H2O2 to MCF-7 cells in culture [95]. Thus, a reasonable 
explanation for the loss of E-cadherin induction under H2O2-containing conditions was a downregulation 
of ERβ expression. To test this, DU145 cells were grown for 24h in either control or WPMY-1 CM -/+ 
H2O2 (10 µM) followed by immunoblotting of whole cell lysate for ERβ.  However, as shown in Figure 
28, H2O2 did not alter ERβ levels. Interestingly, WPMY-1 CM treatment of DU145 cells led to an increase 
in ERβ levels, which may contribute to efficient induction of E-cadherin.  
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Figure 28. CM treatment increases ERβ expression in DU145 cells. 
DU145 cells were grown for 24h in either control or WPMY-1 conditioned media -/+ H2O2 (10 µM). Cells were 
then lysed in RIPA buffer and whole cell lysate was subjected to western blot analysis for ERβ. The blot was 
stripped and re-probed for β-actin to serve as a loading control. Bars represent mean normalized densitometric 
values from 3 independent experiments. A one-way ANOVA followed by Dunnett’s multiple comparison test was 
performed. All values were compared to the control. * p<.05  
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ERβ has the capacity to shuttle between both the nucleus and the cytoplasm. While nuclear ERβ 
localization does not necessarily indicate activity, ERβ acting directly as a DNA-binding transcription 
factor must be nuclear. Thus, a decreased nuclear retention of ERβ is indirectly indicative of less 
transcriptional activity. Although H2O2 did not alter ERβ expression, it did reduce its nuclear retention as 
reflected in a reduced nuclear/cytoplasmic ratio in biochemical fractionation experiments (Figure 29).  
While this is seen in both control and CM conditions, the biological relevance of the effect of H2O2 is only 
seen when the ERβ signaling pathway is activated by an ERβ ligand in the CM. Thus, H2O2 treatment 
alone does not affect DU145 motility, but in the presence of 3β-Adiol (from CM) treatment with H2O2 is 
sufficient to downregulate ERβ signaling by decreasing nuclear retention of the receptor. 
  
89 
 
  
H2O2 Decreases Nuclear Retention of ER-beta in DU145 Cells
(-) (+
) (-) (+
)
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
Control
CM
H2O2 (10 uM)
N
u
c
le
a
r:
C
y
to
p
la
s
m
ic
ra
ti
o
* 
* 
 
Figure 29. H2O2 decreases nuclear retention of ERβ in DU145 cells. 
Nuclear and cytoplasmic lysates were prepared from DU145 cells and subjected to western blot 
analysis for ERβ protein. Results are displayed as densitometric analysis from 3 independent blots. 
A 2-way ANOVA followed by a Bonferroni posttest was performed. *p<.05 
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Previous work has shown that ERβ is sensitive to oxidation and, as a result, exhibits destabilized 
DNA binding. To test if H2O2 was capable of destabilizing DNA binding of ERβ at its target gene E-
cadherin, a chromatin immunoprecipitation (ChIP) assay followed by quantitative RT-PCR was 
performed (Figure 30). Preliminary results demonstrate that there is a significant reduction in 
occupancy by ERβ at the E-cadherin promoter. Three different previously defined ERβ binding sites were 
investigated (unpublished data from the lab of Benita Katzenellenbogen), and all 3 demonstrated 
decreased ERβ binding in cells subjected to H2O2. Importantly, this is consistent with previously shown 
data demonstrating a decreased nuclear retention of ERβ in DU145 cells subjected to H2O2 (Figure 29). 
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Figure 30.  H2O2 decreases occupancy by ERβ at the E-cadherin promoter. 
DU145 cells were treated for 18h with 1% charcoal-stripped FBS phenol-red free medium -/+ H2O2 (10µM). An 
ERβ pulldown followed by deproteination and quantitative RT-PCR using 3 different primer sets for previously 
determined ERβ binding sites within the E-cadherin promoter region was performed. Results are preliminary and 
are representative of a single experiment. qRT-PCR was performed in technical duplicate. 
 
92 
 
3.6 SMIF is an androgenic precursor to an ERβ ligand 
3β-Adiol can be synthesized from a number of androgenic precursors through the enzymatic 
pathway involving 17β-hydroxysteroid dehydrogenases (17βHSD), also known as aldo-keto reductases 
(AKR1C) [7]. DU145 cells express AKR1C enzymes and are capable of catalyzing redox reactions at the 
C17 position of steroid hormones [122, 123]. Previous work has shown that the androgenic precursor 
DHEA can be metabolized to 3β-Adiol through the activity of these AKR1C enzymes; specifically, the 
AKR1C3 subtype can convert DHEA directly to 3β-Adiol [124]. Thus, to test if SMIF was an androgenic 
precursor such as  DHEA that the DU145 cells were metabolizing to an ERβ ligand, I used the known 
AKR1C1-3 inhibitor flufenamic acid (FA) [125]. As Figure 31 shows, exogenous DHEA inhibits DU145 
motility, but this inhibition is lost when FA is present. This indicates that DHEA is capable of inhibiting 
DU145 motility, but it is not a direct effect of DHEA and rather requires metabolism through an AKR1C 
pathway. Additionally, DU145 cells are AR negative. This further suggests that DHEA is exerting its 
effects via a metabolite acting on ERβ rather than through a direct androgen effect. Similarly, FA 
reverses the inhibitory activity of CM, suggesting that DHEA or a similar precursor derived from the CM 
is being metabolized to an ERβ ligand through an AKR1C-dependent pathway.  
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Figure 31. SMIF is an androgenic precursor metabolized by the DU145 cells to an ERβ ligand. 
Flufenamic acid blocks the inhibitory activity of DHEA and SMIF. Wound healing assays were 
performed on DU145 cells in either control or CM using flufenamic acid (50 µM) and DHEA (100 
nM) where indicated. Results are representative of 4 independent experiments, each done in 
technical quadruplicate. A one-way ANOVA followed by Tukey’s multiple comparison test was 
performed. * p <.05 
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The inhibitory effect of CM is lost upon addition of H2O2; consequently, addition of H2O2 to 
DHEA-treated DU145 cells was predicted to reverse the motility suppression, consistent with the 
hypothesis that DHEA is a candidate as the previously-defined SMIF. Addition of H2O2 could potentially 
inhibit either metabolism of DHEA into ERβ ligands, or it could act directly on ERβ and thus simply block 
its activity. Previous experiments demonstrated that the motility inhibition exerted by exogenous 3β-
Adiol is reversible upon addition of H2O2 (see Figure 25), suggesting that the action of H2O2 is at the level 
of ERβ and not simply an alteration in AKR1C metabolizing capacity. To confirm that SMIF could be 
DHEA, exogenous H2O2 was added to a wound healing assay performed on naïve DU145 cells. Figure 32 
demonstrates that addition of H2O2 is capable of reversing the effect of exogenous DHEA in a manner 
similar to that seen when H2O2 is added to CM (see Figure 21). These data suggest that DHEA is a likely 
candidate for the identity of SMIF, and H2O2 serves to inhibit the action of DHEA metabolites by acting 
directly on ERβ in the DU145 cells. 
  
95 
 
  
Addition of  H2O2 Reverses the
Motility Suppression by DHEA
0 5 10 20
0
10
20
30
Control
DHEA
uM H2O2
%
 w
o
u
n
d
 c
lo
s
u
re
 (
2
4
h
)
* 
  
Figure 32. Addition of H2O2 reverses the motility suppression by DHEA. 
Naïve DU145 cells were wounded and treated with either vehicle (control) or DHEA (100nM) 
under increasing concentrations of H2O2. Results are representative of 4 independent 
experiments, each done in technical quadruplicate. Bars represent the mean  SEM. A 2-way 
ANOVA followed by a Bonferroni posttest was performed. * p<.05 relative to all other 
conditions  
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Given these data, a working model was developed to describe the bidirectional communication 
between the stromal and epithelial compartments with respect to the microenvironment’s role in 
cancer cell motility. Figure 33 and Figure 34 are cartoon diagrams indicating the major points of interest 
in the stromal/epithelial communication cascade: First, irrespective of their state of “reactivity”, 
prostate stromal cells have the capacity to produce a precursor (potentially DHEA) to an ERβ ligand that 
is a potent inhibitor of PCa cell motility. Furthermore, locally produced TGF-β1 by PCa cells induces a 
pro-inflammatory and pro-oxidant milieu in TGF-β1 hyper-responsive stromal cells, leading to 
upregulation of Cox-2. Finally, H2O2 produced by Cox-2 blocks the effect of 3β-Adiol derived from 
stromal DHEA by affecting its target ERβ.  
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Figure 33. Stromal fibroblasts exert an inherent capacity to suppress PCa cell motility. 
In a normal fibroblast, DHEA is constitutively produced and secreted. It is metabolized by AKR1C 
enzymes in the DU145 cells into potent ERβ ligands, which then act to limit motility. 
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Figure 34. Stromal myofibroblasts alter the redox status of the local milieu and thus lose their 
inherent capacity to limit PCa cell motility. 
In reactive myofibroblasts, locally produced TGF-β1 stimulates the production of ROS which is 
secreted in the form of H2O2. The H2O2 acts as a second paracrine factor to limit the 
transcriptional activity of ERβ, thus alleviating its inhibitory effect on DU145 motility. 
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4.0 Discussion 
4.1  Summary of findings 
 The work presented here demonstrates that reactive stromal cells retain an inherent regulatory 
control over cancer cell motility through secreted paracrine factors. Specifically, stromal cells secrete an 
androgen metabolite (DHEA?), that is a precursor for a selective ERβ ligand. Activation of ERβ in cancer 
cells following conversion of the stromal produced ligand increases E-cadherin expression and thus 
inhibits cell motility. However, ERβ activity in the cancer cells is reduced following its oxidation by H2O2, 
which is produced by an ROS-generating system in TGFβ treated stromal cells. 
 Both CAFs and the myofibroblastic WPMY-1 cells employ extracellular H2O2
 as a paracrine 
mediator responsible for producing a permissive effect on DU145 cancer cell motility in co-culture. 
Inhibition of this H2O2 restores their inherent ability to limit DU145 motility within this same co-culture. 
COX-2 is the chief producer of local H2O2 by WPMY-1 cells, and specific ablation of COX-2 using an 
shRNA expressing lentivirus is sufficient to restore the inhibitory action of WPMY-1 cells in co-culture. 
 The key stimulatory factor driving the upregulation of stromal COX-2 was determined to be TGF-
β1 produced by the DU145 cells. Inhibition of TGF-β1 in co-culture is sufficient to restore WPMY-1 cells’ 
inherent ability to suppress DU145 motility. While TGF-β1 is constitutively produced, an enhanced TGFβ 
response pathway in the WPMY-1 cells leads to an induction of COX-2 and subsequent H2O2 production. 
The data uniquely demonstrate that it is not a loss of function in the WPMY-1 cells that is responsible for 
their permissive effect on DU145 motility, but rather it is an increased responsiveness within the TGFβ 
signaling pathway that leads to the production of an additional paracrine factor (H2O2) that acts directly 
on the DU145 cells to inhibit the effect of the constitutively produced DHEA/3β-Adiol. 
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 Figure 35 is a simple schematic summarizing the bidirectional paracrine communications 
between the cancer cells and the nearby stromal cells, ultimately resulting in an increased motile 
capacity. 
 
Figure 35. A simple schematic of bidirectional paracrine communications between PCa cells and 
nearby stromal cells. 
Overproduction of TGF-β1 by PCa cells induces COX-2 expression and subsequent H2O2 production in 
nearby stromal cells. H2O2 acts as  paracrine mediator to decrease ERβ activity in the PCa cells, 
subsequently alleviating its anti-motility effects 
 
4.2 Differential responsiveness to locally produced TGF-β1 
 TGFβ signaling has long been regarded as a “double-edged sword” in cancer biology; early in 
carcinogenesis TGFβ is growth suppressive, but as the disease progresses TGFβ becomes cancer 
promoting [77]. Tissue staining of prostatic adenocarcinomas shows enhanced phospho-Smad2 staining 
in the stroma, suggesting that the TGFβ cascade is hyperactive [82]. Additionally, staining for TGF-β1 has 
shown to be significantly higher in PCa specimens [126].  
The model employed herein coincides perfectly with these observations: the DU145 PCa cells 
secrete relatively high levels of active TGF-β1, and the WPMY-1 cells demonstrate an enhanced 
responsiveness. WPMY-1 cells show a greater transcriptional response to exogenous TGF-β1 than their 
more fibroblastic PS30 counterparts. Furthermore, the WPMY-1 cells express significantly higher levels 
of several Smad proteins, which are mediators of the canonical TGFβ signaling pathway.  Both the 
elevated transcriptional activity and the increased expression of Smad proteins suggests that WPMY-1 
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cells have acquired an increased responsiveness to TGFβ. Recent work has shown that TGFβ receptor 
(TGFβR) heterogeneity in stromal cells is necessary for promotion of carcinogenesis [82, 88]. While some 
stromal cells lose TGFβR expression, the cells which retain active TGFβ signaling demonstrate an 
enhanced responsiveness. This enhanced responsiveness leads to the negative effect of TGFβ signaling 
in cancer progression, as unchecked signaling leads to the “wound that never heals” phenotype. The 
WPMY-1 cells demonstrate the detrimental effect of enhanced TGFβ signaling on cancer cell motility. 
While TGFβ is well established as the responsible factor for transdifferentiation of prostatic 
fibroblasts into myofibroblasts [66], this project has shown it maintains crucial effects beyond inducing 
this initial phenotypic change. An enhanced responsiveness to TGF-β1 in the WPMY-1 cells results in the 
chronic activation of components of the wound healing cascade, most importantly the stimulation of 
COX-2 expression. The importance of this is underscored when a TGF-β1 neutralizing antibody is added 
to DU145/WPMY-1 co-culture and a dramatic inhibition of DU145 motility is observed. The novelty lies 
in the capability of the WPMY-1 cells to inhibit DU145 cell motility in the absence of active TGF-β1. This 
shows that myofibroblasts retain the ability to impose inherent control over cancer cell motility, but this 
effect is negated through the production of a second paracrine factor produced downstream of TGFβ 
signaling. 
In the model of stromal heterogeneity, loss of TGFβ signaling in some of the stromal cells leads 
to a subsequent overproduction of TGF-β1 by the neighboring cancer cells in an effort to favorably 
modulate the microenvironment [82, 88, 126]. Thus, in stromal cells maintaining intact TGFβ signaling, 
abundant TGF-β1 is present to ensure a robust activation of the TGFβ pathway. Potent activation of the 
TGFβ pathway in stromal cells results in a permissive effect on cancer cell motility, as seen when DU145 
cells are co-cultured with WPMY-1 cells. This permissive effect allows the cancer to move and infiltrate 
unrestrained, eventually leading to invasion of surrounding tissues and distant metastases. 
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4.3  COX-2 in the prostate stroma 
In WPMY-1 cells, TGF-β1 induces expression of the pro-inflammatory enzyme COX-2. As a 
byproduct of its enzymatic activity, COX-2 generates H2O2, which acts a second paracrine factor to 
inhibit ERβ activity in the cancer cells. 
COX-2 is a multi-faceted enzyme whose expression is generally labile and transient. In some 
diseases such as PCa, however, consistently high levels of COX-2 are associated with worse prognosis 
[86, 106]. It is important to understand the expression profile of COX-2 more completely, since the 
cancer cells themselves often overexpress COX-2. Addition of selective pharmacologic inhibitors of COX-
2 has been shown to decrease cancer cell growth, induce apoptosis, and decrease tumor size in animal 
models [106]. Interestingly, it is not simply COX-2 expression by the cancer cells that is responsible for 
increased aggressiveness. A xenograft of Lewis lung carcinoma cells (positively expressing COX-2) was 
unable to form a tumor in a COX-2 -/- host, suggesting that stromal COX-2 is necessary for tumor 
development. Upon further investigation, it was found that the COX-2 -/- fibroblasts were unable to 
secrete VEGF, an obligatory requirement for tumor formation [114]. Similarly, DU145 cells secrete TGF-
β1 which increases expression of stromal COX-2 in WPMY-1 cells and hence the production of H2O2, thus 
granting them reprieve from the motility-suppressive effects otherwise imposed. Figure 36  is from a 
study done in 2010 by Richardsen et al. showing that high expression of COX-2 in the stroma correlates 
with decreased disease-specific survival [86]. These clinical data are in accordance with the work 
presented herein which demonstrates that upregulation of stromal COX-2 can inhibit the motility 
suppression normally offered by the surrounding stroma through inactivation of ERβ in the cancer cells. 
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Figure 36. High stromal COX-2 staining correlates with decreased survival in patients with primary 
PCa. 
In both non-metastatic and metastatic primary PCa, high expression (green line) of COX-2 trends with a 
shorter disease-specific survival time. 
Adapted from E. Richardsen at al./Cancer Epidemiology 34 (2010) 316-322 
 
In addition to COX-2 expression alone as a predictor of survival, another study  showed that 
COX-2 staining is inversely related to E-cadherin expression in neighboring cancer cells [127]. Loss of E-
cadherin expression is associated with EMT and subsequently with increased migration and invasion 
[128]; similarly, increased stromal COX-2 staining is associated with a poorer prognosis in PCa and others 
[115, 129]. The data presented herein demonstrate a molecular basis for this observation. Induction of 
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COX-2 increases H2O2 production by stromal cells, which acts directly on ERβ in cancer cells both by 
preventing its DNA binding and decreasing its nuclear retention. ERβ is thus unable to adequately bind 
and activate the E-cadherin promoter, hence a loss of E-cadherin expression. Since even a myofibroblast 
is capable of secreting a precursor leading to the production of potent ERβ ligands, use of a selective 
COX-2 inhibitor could potentially restore the expression of E-cadherin and subsequent inherent motility 
suppression endogenously offered by the stroma. 
Clinical trials with NSAIDs (non-selective COX inhibitors) have had ambiguous results in PCa [112, 
113]. In a simplified system such as a 2 cell indirect co-culture, it may be an oversimplification to assume 
that the redox status of the milieu is controlled solely by ROS produced during COX-2 enzymatic activity. 
However, the data presented in this work clearly validate the role of extracellular H2O2 as a crucial 
paracrine factor affecting the cancer cells. Rather than use selective COX-2 inhibitors alone for cancer 
treatment, it would logically follow to use a combination therapy approach of a COX-2 inhibitor and an 
antioxidant. Inhibiting COX-2 would significantly decrease the inflammatory nature of the 
microenvironment, and an antioxidant would further inhibit any ROS produced by redundant or parallel 
pathways. 
4.4 Intraprostatic steroid metabolism and estrogen signaling 
 As men age, serum testosterone levels naturally decline and the main source of androgens shifts 
to adrenal DHEA [7]. However, a concomitant equilibrium of estrogen levels leads to decrease in the 
testosterone to estrogen ratio (T:E) [43]. This observation has led to extensive work studying the role of 
estrogens in the prostate. Aromatase is the enzyme responsible for aromatic conversion of androgens to 
estrogens, and high local expression of aromatase within the prostate ensures adequate intraprostatic 
estrogen synthesis. Work by Gail Risbridger et al. demonstrated that an aromatase-knockout mouse 
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model is unable to form PCa despite chronically elevated levels of circulating androgens, thus 
highlighting the crucial role for estrogenic signaling in abnormal prostate pathology [43].  
 However, ERβ activation within the prostate is due largely to androgen metabolites rather than 
estrogens [56]. Quantitative real-time PCR of both PCa cell lines and patient-derived tumor samples 
revealed elevated levels of the enzyme AKR1C3, which is responsible for the conversion of the 
androgenic precursor DHEA into the ERβ ligand 3β-Adiol [61]. Additionally, the prostate expresses 
AKR1C1 and AKR1C2, both of which catalyze the conversion of the potent androgen DHT into the ERβ 
ligands 3β-Adiol and 3α-Adiol, respectively [63]. Analysis of PCa specimens revealed limited expression 
of enzymes responsible for de novo steroidogenesis, indicating that the conversion of androgenic 
precursors is the predominant method of controlling the balance in androgenic and estrogenic signaling 
pathways [61].  
Consistent with this concept of intraprostatic steroid metabolism and estrogenic signaling, the 
data presented herein demonstrate that DU145 PCa cells are capable of metabolizing locally produced 
DHEA into potent ERβ ligands. Inhibition of AKR1C1-3 with flufenamic acid abolished the motility-
suppressive effects of both exogenous DHEA and WPMY-1 CM, indicating that metabolism through an 
AKR1C-dependent pathway is necessary for DHEA to exert its inhibitory effects. Additionally, addition of 
an ERβ antagonist to WPMY-1 CM blocked its inhibitory effects on DU145 motility, indicating that its 
inhibition is through an ERβ-dependent mechanism. Constitutive production of DHEA or other selective 
ERβ ligand precursor by the stroma may serve to inherently limit cancer cell motility by increasing cell 
adhesion through induction of E-cadherin. Upon transdifferentiation into myofibroblasts, stromal cells 
gain additional characteristics that lead to further paracrine signals to the cancer cells, but they maintain 
the ability to produce DHEA as a paracrine mediator capable of inhibiting motility. Perturbations in this 
DHEA/3β-Adiol/ERβ pathway could potentially increase the risk of PCa development by allowing excess 
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motility and loss of E-cadherin expression in epithelial cells. Consistent with this prediction, several 
studies have shown an increased risk of PCa development in men with genetic polymorphisms in AKR1C 
enzymes that render them less active [62, 130]. Future therapeutic paradigms should take into account 
the retained ability of the stroma to inhibit cancer cell motility through an ERβ-dependent pathway, and 
should focus on creating a microenvironment favorable to maintenance of ERβ activity by controlling 
the redox status of the local milieu.   
Epidemiological support for ERβ’s role in negatively regulating PCa is seen in tissue staining done 
by Mak et al. which demonstrates that E-cadherin expression is directly correlated with ERβ expression 
in PCa [56]. Loss of E-cadherin is a known marker for EMT, which is associated with loss of cell adhesion 
and a subsequent increase in cell motility [131]; thus, loss of ERβ expression is directly associated with 
increased motility and aggressiveness. In fact, ERβ expression is inversely related to the progression of 
PCa to a high Gleason grade [56].  Figure 37 below is adapted from work performed by Mak et al. and 
shows tissue staining from normal and Gleason grade 3 and 5 PCa specimens. Loss of ERβ coincides with 
a loss of E-cadherin expression and is seen in the higher Gleason grade sample; these data are consistent 
with the work presented herein which demonstrates that activation of ERβ signaling in DU145 PCa cells 
via a paracrine mediator in CM induces expression of E-cadherin. 
 
 
 
 
 
 
 
107 
 
 
 
 
 
 
4.5  Redox-sensitivity of ERβ 
 Previous work has shown ERβ to be susceptible to oxidation at various cysteine residues within 
one or both of its zinc fingers [52, 53]. A significant number of patients with breast cancer who fail to 
respond to the anti-estrogen tamoxifen have been shown to have structural defects in their ER which 
prevents it from stably binding DNA [54]. Importantly, transient exposure to oxidants results in a 
reversible oxidation of ERβ, but chronic exposure to free radicals and/or ROS ultimately leads to an 
irreversible alkylation and permanent loss of DNA binding [52]. Additionally, work done in the breast 
cancer cell line MCF-7 revealed that oxidative stress, specifically H2O2, was able to alter expression levels 
of ERβ [95]. These data expound upon the sensitivity of ERβ activity to the local redox status and 
highlight the importance of limiting chronic ROS production. 
 
Figure 37. ERβ expression is directly correlated with E-cadherin expression. 
Tissue staining of specimens from either normal or cancerous prostate. In normal and low Gleason grade PCa 
ERβ is localized to the nucleus and E-cadherin expression is seen throughout the epithelium. In Gleason grade 
5, ERβ staining is absent and E-cadherin expression is lost. 
Adapted from P. Mak at al./Cancer Cell 17 (2010) 319-332 
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 Similarly, the results presented in this work demonstrate that ERβ is unable to activate its target 
gene E-cadherin in DU145 cells when H2O2 is present in the growth media, either from local production 
by the stromal cells or through exogenous addition. H2O2 pretreatment of the CM followed by 
neutralization was unable to obtain a permissive effect on DU145 motility in a wound healing assay, 
indicating that the H2O2 was acting directly on the DU145 cells. Inclusion of an ERβ antagonist abolishes 
the inhibitory effect of CM, showing that ERβ is the target of SMIF in the DU145 cells. The known potent 
redox-sensitivity of ERβ thus explains why the addition of H2O2 is capable of negating the motility-
inhibitory activity of CM. 
 In the co-culture model employed herein, ERβ in the DU145 cells could be directly oxidatively 
modified by H2O2 produced by the WPMY-1 cells and thus exhibit decreased DNA binding at the E-
cadherin promoter. Preliminary data demonstrates decreased occupancy by ERβ at the E-cadherin 
promoter in the presence of H2O2, which also coincides with the observation that H2O2 treatment 
decreases nuclear retention of ERβ. This decreased promoter binding would result in decreased 
transcription of E-cadherin and a subsequent permission of cell motility, both of which were shown to 
occur. H2O2 did not affect protein levels of ERβ in the DU145 cells, thus suggesting that oxidative stress 
signaling is affecting ERβ activity directly and not simply regulating its expression. In addition to direct 
effects on ERβ binding at the E-cadherin promoter, H2O2 could be acting to alter the composition of the 
transcriptional complex that is recruited. Work done by Saijo et al. showed that the transcriptional 
complex recruited by ERβ differs when the activating ligand is Adiol as opposed to estradiol [124], 
suggesting that differential coactivator or corepressor recruitment is another potential mechanism for 
distinct actions of ERβ. 
 While the mechanism by which H2O2 decreases ERβ activity in the DU145 cells remains yet to be 
elucidated, the overall impact of the redox-sensitivity of ERβ is clear. Increased H2O2 leads to a decrease 
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in ERβ activity and a subsequent reduction in E-cadherin; both decreased ERβ and E-cadherin are 
directly correlated with progression of PCa to a worse Gleason grade, underscoring the importance of 
maintaining adequate ERβ function in the prostate [56]. The work presented herein suggest that 
neutralizing ROS/ H2O2 production by the stroma can serve as one mechanism by which ERβ activity 
remains unimpaired.  
4.6 Clinical Implications 
 The overarching theme demonstrated by this work is the crucial role oxidative stress plays in 
altering steroid receptor signaling within the cancerous prostate. The role of the tumor 
microenvironment can change from inhibitive to permissive simply by paracrine signals generated by 
the cancer cells in an effort to escape intrinsic control. Cancer cells are elusive to many therapies due to 
an unstable genetic composition, making selective targeting a difficult therapeutic task. Thus, 
development of therapeutic paradigms that capitalize on the intrinsic regulatory mechanisms of the 
microenvironment could be a crucial step in targeting the molecular mechanisms underlying growth and 
dissemination of adjacent cancer cells.  
 This project identifies an inherent capacity of myofibroblasts and CAFs to limit PCa cell motility 
given an inhibition in oxidative stress signaling within the local milieu. Constitutive production of DHEA 
or other androgenic precursor by the stroma leads to generation of ERβ ligands in an AKR1C-
dependnent pathway within the cancer cells, and these ligands serve to activate ERβ and subsequently 
increase E-cadherin expression, ultimately leading to a decrease in cell motility. Pharmacologic inhibitors 
of COX-2 are available, and they could serve to limit production of ROS within the stroma. Additionally, 
antioxidants could potentially be administered to further decrease the oxidative stress placed on the 
PCa cells and thus permit intact ERβ signaling. Notably, this work demonstrated that even aggressive 
PCa cells maintain the inherent molecular machinery to produce potent ERβ ligands given an adequate 
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precursor, and they retain the ability to revert to a less motile phenotype in response to ERβ signaling. 
This could justify the development of synthetic ERβ ligands to activate the protective mechanisms 
incurred by this pathway. Halogen-substituted indazoles have been shown to exhibit anti-inflammatory 
activity in microglia through an ERβ-dependent pathway in vivo [124], underscoring the viability of 
synthetic ERβ ligands as potential future therapeutic agents.  
4.7  Future Directions 
 The benefit of DHEA metabolism in the prostate remains an area of debate; a recent review 
concluded that in normal prostate, DHEA has no deleterious effects, but in the diseased prostate a 
reactive stromal component leads to altered DHEA metabolism and increased androgenic signaling 
[132]. Specifically, it has been shown in an in vitro co-culture model that TGF-β1 induced 
transdifferentiation of stromal cells leads to increased androgenicity of DHEA in the cancer cells, as 
measured by increased PSA secretion [132]. DHEA can have direct effects on ERβ as demonstrated in a 
binding assay which showed a higher affinity of DHEA for ERβ as opposed to either ERα or AR [133] but, 
more importantly, DHEA’s role is primarily a precursor to either estrogenic or androgenic steroids [134].  
Based on the work presented here, I would hypothesize that it is not an alteration in DHEA metabolism 
that leads to increased androgenic signaling in the presence of a reactive stroma, but rather it is the loss 
of ERβ activity that leads to a subsequent increase in AR action through loss of competition.  
Advanced technologies such as ChIP-on-chip and ChIP-seq have allowed the identification of cis-
acting targets (i.e. DNA binding sites) by trans-acting  factors (i.e. transcription factors, in this case 
steroid receptors). The unique signature of a specific transcription factor on a genome-wide scale is thus 
referred to as its cistrome, which collectively identifies all of the target genes possessing direct binding 
sites for the specified transcription factor [137]. Work recently published from Myles Brown et al. used a 
ChIP-seq approach to show a unique AR cistrome in ER(-) as compared to ER(+) breast cancer [135]. This 
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is consistent with the hypothesis that increased DHEA androgenicity in PCa cells when co-cultured with 
reactive stroma could be due to a differential activation of AR target genes following loss of ERβ activity. 
Additionally, it has recently been shown that cross-talk between multiple transcription factors occurs 
preceding activation of some target genes [136]; by extension, it can be hypothesized that inactivation 
of ERβ via oxidation could disrupt cross-talk between it and AR and thus tip the balance in the direction 
of AR and androgenic signaling. This concept of steroid-receptor cross-talk and the resulting AR 
transcriptional imprint that differs as a result of loss of activity of ERβ is an area that remains largely 
unexplored as of yet. While castrate-resistant prostate cancer (CRPC) is defined by a lack of response to 
androgen deprivation, the PCa cells actually retain AR-dependence but their AR becomes more 
promiscuous and is activated by additional growth factors [30-34]. Using this model of CRPC, which 
represents advanced disease, one could seek to understand whether a loss of functional ERβ contributes 
to a different genomic signature of AR and thus leads to androgenic signaling in the absence of potent 
androgens. Specifically, I would determine if the AR cistrome differs in CRPC cells in response to both 
androgens and ERβ ligand precursors when ERβ is non-functional or absent. I would predict that in the 
absence of functional ERβ, DHEA or a similar precursor still undergoes the same metabolic conversions, 
but AR activity is enhanced due to a lack of competition from ERβ.  
Furthermore, while Adiol is known to bind ERβ with a much higher affinity than either ERα or 
AR, in the absence of functional ERβ any Adiol produced has the potential to bind another available 
steroid receptor. This could lead to activation of pro-inflammatory pathways (ERα activation) and 
increased migration and proliferation (AR activation) simply by disrupting the balance of steroid 
receptor competition and cross-talk within the prostate. Using an RNA-seq approach,  I would 
investigate the activation of both ERα and AR target genes in response to DHEA in CRPC cells in which 
ERβ has been selectively knocked down, hypothesizing that in the absence of functional ERβ both ERα 
and AR activity is increased. RNA-seq would allow gene expression profiling by measuring mRNA levels, 
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thus providing a powerful tool for analyzing the expression of AR and ERα target genes in CRPC cells 
lacking functional ERβ. The depth of information gained from this approach, however, will necessitate 
further analysis using pathway mapping tools, but I would predict to see an increase in inflammatory 
genes (stemming from increased ERα activation) as well as genes involved in cell proliferation, 
migration, and invasion (resulting from increased AR activation). 
Additional future work might aim to better identify the mechanisms by which oxidative stress 
limits ERβ activity. Specific experiments such as chromatin immunoprecipitation (ChIP) have already 
produced preliminary data, and would be repeated to more confidently characterize the DNA-binding 
affinity of normal and oxidized ERβ at the E-cadherin promoter. Furthermore, a Western blot for 
oxidized proteins could be utilized to determine to what extent ERβ is oxidized in DU145 cells following 
exposure to physiological levels of H2O2 [138]. Additional experiments can be designed to determine if 
the oxidation of ERβ under these circumstances is reversible, and if ERβ activity can be restored 
following treatment of DU145 cells with either antioxidants or thiol-reducing agents. 
Recent work has begun to uncover the importance of chromatin remodeling in gene activation, 
as elegantly shown by Susanne Mandrup et al. [136]. This group identified unique transcriptional 
“hotspots” (defined as co-occupancy by 2 or more transcription factors) that vary at different time 
points during adipogenesis. Building upon this same theory, studies would be designed to investigate 
ERβ activity at the E-cadherin gene at various time points. Moreover, the composition of various co-
activator and co-repressor complexes that are recruited to the E-cadherin promoter along with ERβ 
following activation of the receptor by an androgen metabolite would be determined. Differential 
recruitment within the transcriptional complex could potentially underlie the different effects seen 
when ERβ signaling is activated under oxidative stress conditions, and this could again provide valuable 
information for the identification of future therapeutic targets. 
113 
 
Additionally, in vivo studies looking at the role of oxidative stress and ERβ in cancer cell motility 
will play an important role in further understanding the clinical implications of this work.  A xenograft of 
WPMY-1/DU145 cells implanted under the renal capsule in a mouse model would provide the most 
simplistic method for studying paracrine interactions influencing cell motility in vivo. The sub-renal 
capsule model provides a method for easily measuring migration of PCa cells into surrounding normal 
tissue, and the near proximity of ample vasculature provides a method for hematogenous spread by 
more aggressive PCa cells. Using this model, I would treat with titrating doses of either a selective COX-2 
inhibitor or antioxidants and upon sacrificing the animal I would look for evidence of increased motility 
(spread into adjacent structures or distant metastases) and decreased cell adhesion (E-cadherin staining 
within the implanted tumor). I predict that the co-administration of COX-2 inhibitors or antioxidants 
would significantly decrease the spread of the tumor and lead to an appreciable increase in E-cadherin 
expression. Importantly, I would isolate ERβ from tumor samples and assay its DNA-binding activity, 
hypothesizing that ERβ isolated from tumors in the absence of COX-2 inhibition or antioxidants would 
exhibit less DNA binding affinity due to oxidation. This in vivo work could highlight the importance of 
limiting oxidative stress within the prostate in order to take advantage of an inherent regulatory 
mechanism offered by the adjacent stromal cells regardless of their state of transdifferentiation.  
The role of estrogens in the prostate is an emerging field displaying great therapeutic potential. 
However, past experience of using androgen-deprivation therapy has shown that targeting only one 
steroid receptor loses efficacy in a short period of time. It is likely to be an oversimplification, then, to 
suggest targeting only ERβ for limiting cell motility in PCa. Much of the future work proposed here 
suggests critical work for understanding the delicate balance between AR and ERβ in PCa. Over 20% of 
human cancers are associated with chronic inflammation, with prostate cancer often following the trend 
[132]. The redox-sensitivity of ERβ leaves it susceptible to a decrease in activity, perhaps favoring 
signaling through AR-dependent pathways. A better understanding of ERβ activation in the prostate, 
114 
 
coupled with the knowledge of how it affects AR, could potentially lead to highly specific therapies that 
intervene at key points to intercept multiple signaling pathways and thus provide greater clinical 
success. 
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